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Introduction
The term Laryngopharyngeal Reflux (LPR) was coined by James and is accepted by
the American Academy of Otolaryngology: Head and Neck surgery.[1] Laryngopharyngeal
reflux disease (LPRD) was first described by von Leden and Moore, in the 1960, but it did
not come to the forefront of otolaryngology practice until Koufman’s landmark thesis on the
subject in 1991.[1,2] Laryngopharyngeal reflux disease is an extraesophageal variant of
gastroesophageal reflux disease that affects the larynx and pharynx.[3,4] The other terms used
for this in otorhinolaryngology practice are ‘extra esophageal reflux’, ‘chronic laryngitis’
and ‘supra esophageal complication of gastroesophageal reflux’.[4] Recent studies in this
field evidently proves that laryngopharyngeal reflux represents a complex spectrum of
abnormalities and it is therefore important to understand the basic scientific concepts
relevant to this disease and also the appropriate clinical care of patients with
laryngopharyngeal reflux.
Laryngeal abnormalities may be caused either by direct injury or damage by a
secondary mechanism.[5-7] It has been shown experimentally that as few as three reflux
episodes per week can produce severe laryngeal damage.[1] Direct injury occurs when acid
and pepsin comes into contact with laryngeal mucosa, resulting in mucosal damage.[6,8]
Irritation of the distal esophagus by acid may cause a reflux mediated by the vagus nerve,
resulting in chronic cough and throat clearing which may in turn produce traumatic injury to
laryngeal mucosa.[7,9]
The incidence of patients presenting to an Otolaryngologist with GERD has been
estimated to be 4% to 10%.[10] As otolaryngologists are now more diligent in looking for
signs of laryngopharyngeal reflux, such as posterior laryngeal edema and erythema,
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obliteration of the laryngeal ventricles and inter arytenoid hypertrophy.[2,11] The treatment
for laryngopharyngeal reflux based on these findings has become increasingly common.[2,12]
Though Laryngopharyngeal reflux disorder is a common scenario in clinical practice, it is
usually under reported, misdiagnosed or neglected for want of a definitive diagnosis.
Because of the lack of convincing evidence regarding diagnostic techniques, causation in
individual patient and deficient studies that have produced conflicting conclusions; the
diagnosis and management of LPRD remains controversial.
The prevalence of laryngopharyngeal reflux disease is very high.[13,14] There are no
epidemiological studies to show us the prevalence of laryngopharyngeal reflux disease in
India. According to Koufman, 50% of all patients presenting to their centre with laryngeal
and voice disorders had laryngopharyngeal reflux as documented by dual pH probe
studies.[13,15]
Because of the high prevalence of the disease and potential serious consequences
including laryngeal carcinoma, it is important to be familiar with contemporary perspectives
on this disorder.[13,16,17] In this study, we would like to evaluate whether proton pump
inhibitor therapy would aid in reducing the abnormal ‘reflux finding score’ in
laryngopharyngeal reflux disease.[18]
Hypothesis
Proton pump inhibitors are effective in the treatment of Laryngopharyngeal reflux
disease.
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Aims and objectives:
1. To study the effect of proton pump inhibitors on laryngeal reflux symptom
index.
2. To study the effect of proton pump inhibitors on laryngeal reflux finding
score.
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3. REVIEW OF LITERATURE
3.1. Problem Statement
3.1.1. Prevalence:
Because of its variable presentation, the accurate estimate of the incidence of
Laryngopharyngeal reflux is not available.[13,14] It goes undiagnosed most often, going by the
data provided by the so considered gold standard investigation; pH probe study, which is an
invasive technique. The patient consults the General Physician initially and later is seen by the
otolaryngologist when the cough becomes chronic and does not respond to antibiotic therapy
or when dysphonia develops.[19,20]
3.1.2. Use of proton pump inhibitor
An empiric trial with twice daily PPIs is not only considered the reasonable treatment
for suspected laryngeal and pharyngeal dysfunction related to the reflux, but also has been
recommended as a reasonable diagnostic measure in the management of the reflux.[21] A
positive response to the treatment, confirms the clinical suspicion that the symptoms being
treated are related to reflux.[22]
3.2. Definition
Gastro esophageal reflux is defined, as the retrograde movement of material from the
stomach to esophagus in the absence of belching or vomiting.[3,18,23,24] Gastro-oesophageal
reflux disease occurs when the aforementioned is associated with symptoms or
complications.[23] When gastro esophageal reflux affects the laryngopharynx, the disease
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entity is called Laryngopharyngeal reflux (LPR).[1] The World Congress of Gastroenterology
in Montreal, Canada 2005 defined GERD as “a condition which develops when the reflux of
stomach contents cause troublesome symptoms and/or complications”.[23] Another term used
to describe non esophageal manifestations of regurgitation of gastric contents is extra-
esophageal reflux (EER).[10,13,26]
There are different systems for the classification of the reflux process. The disease
may be classified according to the location of the symptoms (esophageal Vs extra
esophageal), by the presence of tissue injury (erosive Vs non-erosive reflux disease), and by
pH contents of the refluxate (acidic Vs weakly acidic Vs alkaline). Weakly acidic reflux,
previously referred to as non-acid reflux, is more likely to be associated with non-erosive,
extra-esophageal disease.[27]
Fig:1 Montreal Classification [23]
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3.3. Pathophysiology
The esophagus is the conduit for the transfer of material from the pharynx to the
stomach. Gastro esophageal reflux as well as Laryngopharyngeal reflux occurs due to the
pressure gradient between the positive intra-abdominal pressure and the negative intra-
thoracic or intra-hypopharyngeal pressure. The esophagus acts as a vent for the stomach
allowing some normal retrograde flow of gases and gastric contents. There are several
mechanical and chemical safeguards in place to prevent inflammation and tissue injury from
refluxed gastric contents. The mechanical protectors include the lower and upper esophageal
sphincters, the angle of esophageal hiatus at the diaphragm, and gravity. The gate keepers for
the ingress and egress of material are the upper esophageal sphincter (UES), and lower
esophageal sphincter (LES).
LPR has been implicated in several clinical disorders, including
Chronic laryngitis, [1,13,28]
Chronic dysphonia, [1,13,28]
Laryngotracheal stenosis, [29,30]
Head and neck carcinoma, [31-35]
Cough, [36-42]
Asthma, [36,39,40,43-45]
Otitis media, [46]
Dental carries and erosion, [47,48]
Vocal fold granulomas and ulcers, [36,49-51]
Laryngeal papilloma, [52]
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Laryngospasm, [53-56]
Recurrent croup, [57]
Paradoxical vocal fold movement disorder and [58,59]
Laryngomalacia [60]
The agents responsible for producing upper airway symptoms in laryngeal pathology
are acid, pepsin, bile acids and trypsin. Pepsin in combination with gastric acid has been
found to be the most injurious agent with a significant association with laryngeal lesions.[6]
The reflux substrate can be composed either by gas, liquid or mixed (gas/liquid). The
vast majority of the pharyngeal reflux substrate is gaseous without pH drops and is seen
equally in healthy subjects and patients with laryngitis, while mixed refluxes, liquid refluxes
and also gaseous refluxes with pH drops are significantly more common in LPR patients.[61]
The four main constituents in the barrier to the reflux are UES, LES, esophageal acid
clearance, and epithelial resistance.[1,62] Laryngopharyngeal disease associated with EER is
thought to result from both direct and indirect pathways.[3,64,65]
3.3.1. Upper esophageal sphincter
Upper esophageal sphincter (UES) is functionally defined as the area of the distal
pharynx and proximal esophagus that maintains a closed pharyngo esophageal segment and
opens for specific physiologic demands like swallowing and belching.[66] Anatomically, the
upper esophageal sphincter is made up of cricopharyngeus, thyropharyngeus, and proximal
cervical esophagus.[65,67-70] Unlike other muscular sphincters, UES is not a complete muscular
circle but a C – shaped sling that is attached to the cricoid cartilage. The pharyngeal plexus
innervates the upper esophageal sphincter and receives contributions from the vagus nerve,
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and sympathetic nerves from the superior cervical ganglion.[67] The motor neurons that control
the cricopharyngeus are from nucleus ambiguous in the brainstem, and stimulation of the
nucleus tract us solitaries (the afferent nucleus of vagus) results in contraction of
cricopharyngeus.[68] Sensory information from UES is transmitted via the glossopharyngeal
nerves and sympathetic nerves.
Fig 2: Upper Esophageal Sphincter
The UES maintains a closed pharyngo-esophageal segment via tonic contraction of the
cricopharyngeus. During swallowing, UES relaxes and the cricoid cartilage is pulled upwards
and anteriorly by the laryngeal musculature, thereby resulting in the stretching of the
Review of literature
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cricopharyngeus, thus allowing passage of bolus. The UES tonic pressure is increased in
response to laryngeal stimulation (laryngo – UES contractile reflex).[67] UES pressure is
increased with acidification of the distal esophagus and slow balloon distention of the distal
esophagus. General anaesthetics, sleep state, cigarette smoking and peppermint consumption
are associated with decreased UES pressure.[67]
The UES is the final gatekeeper in the antireflux barrier, and UES dysfunction may be
associated with head and neck manifestations of EER.[71]
3.3.2. Lower esophageal sphincter
The LES is the most critical antireflux defense mechanism.[72] It is located at the
gastro-esophageal junction, and is not as anatomically distinct as the UES. Contraction of the
LES results in a circular closure that prevents the egress of gastric contents. Relaxation of the
LES occurs during swallowing, belching and vomiting. The LES is anatomically surrounded
by the diaphragmatic crura, which mechanically augments the sphincter mechanism and
contributes to 25% of LES competence.
Manometric measurements at the LES reflect the combined contribution of the LES
and the diaphragmatic crura. The intrinsic resting pressure of LES varies with each phase of
respiratory cycle, due to differential diaphragmatic contraction.[73] As a result of greater
diaphragmatic activity during episodes of straining, LES pressure is increased yielding a
stronger diaphragmatic squeeze of the LES. Hormonal control of LES activity is complex.
Gastrin, pitressin, angiotensin II, and motilin increase contractile tone whereas secretin,
cholecystokinin, glucagon, and vasoactive intestinal peptide reduce LES pressure.[74-76]
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To prevent GER, LES must maintain a resting pressure that is higher than the gastric
pressure.[75] GER occurs when there is a reversal of the gastric to the LES pressure gradient.
Retrograde flow occurs with relaxation of the LES, with chronic hypotonia of the LES, or
with increase in gastric pressure that overcomes the LES resting pressure. Transient relaxation
of LES occurs in normal healthy adults and children. Transient relaxation of LES (TLESR) is
the most critical mechanism in the production of GER. [77,78] Chronic hypotonia of the LES is
thought to be associated with GER episodes in a small percentage of patients, with the
esophagitis component being more severe. Lower LES resting pressures are seen in patients
with CREST syndrome (Calcinosis, Raynaud’s phenomenon, esophageal dysmotility,
sclerodactyly, and telangectasia), scleroderma, and isolated Raynaud’s phenomenon. Large
hiatal hernias may result in disruption of the relationship of LES with the diaphragmatic crura,
which may in turn impair the ability of the LES to act as an antireflux barrier by removing the
additional pressure generated by the squeeze of the diaphragm.[73,79]
When gastric pressure exceeds LES pressure, reflux occurs. Stress reflux is seen with
increased intra – abdominal pressure during bending over, heavy weight lifting, straining and
coughing.[1] Excessive gastric distention resulting in higher gastric pressures can occur
postprandially after a heavy meal and lead to severe gastroparesis. Impaired gastric emptying
is more common in patients with GERD.[80] Pregnancy during which abdominal pressure is
increased is a risk factor for GERD.[81]
LES sphincter may be affected by medications such as calcium channel blockers
(prescribed for hypertension and cardiac disease) and progesterone as well as by tobacco and
caffeine.[27,81]
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Fig 3: Lower Esophageal Sphincter
3.3.3. Esophageal acid clearance
The esophagus’ innate ability to clear itself of ingested and refluxed materials depends
on its motility, including peristalsis and secondary swallows. It has been hypothesized that
differences in esophageal motility is a major factor that differentiates the clinical profile
between patients with laryngeal and pharyngeal symptoms and those with typical reflux.[82]
Patients with LPR tend to be day time or upright refluxers, in contrast to patients with GERD,
who have more classic night time supine reflux.
Esophageal peristaltic waves along with the effect of gravity, helps in mechanically
clearing the esophagus.[73] Weakened/ ineffective peristalsis permits the refluxed materials to
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have a longer contact time with esophageal tissues. Primary esophageal peristalsis has been
shown to be identical in normal controls and in patients with GERD & posterior laryngitis. [70]
In patients with GERD, secondary esophageal peristalsis was noted to be decreased in
comparison to that in normal controls.[73] Increased number of GER episodes seen in patients
with GERD, when supine, can be partially explained by the loss of gravitational effects.
3.3.4. Chemical protection
Chemical protection from refluxed material starts in the oral cavity with salivary
bicarbonate which serves as a buffer to neutralize acid material. Acidic refluxate left in the
esophagus can be neutralized by gastric glandular secretions and buffering agents in the
saliva.[27]
When salivary flow is compromised and less bicarbonate is available in the alimentary
tract, the acid content present, has a greater opportunity to effect tissue damage. Eg: Sjogren’s
syndrome, in which the salivary glands are not able to produce adequate volume of saliva. A
similar effect may also be seen as a by- product of aging, radiotherapy or medical therapy;
reduced salivation is seen as a side effect with various medications including antihistamines,
antidepressants, and some diuretics.[27]
The low pH of gastric material is damaging to the epithelium, but even alkaline pH,
pancreatic & bile juices, when present can also injure tissues.
Recent investigations suggest that laryngeal tissues are also protected from reflux damage by
a carbonicanhydrase in the mucosa of the posterior larynx.[83]
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3.3.5. Epithelial resistance factors
The esophagus has certain protective mechanisms that can prevent mucosal injury and
reflux; whereas the pharynx and larynx do not. Therefore it takes much less acid/pepsin to
cause tissue damage in the larynx and pharynx than in esophagus.[15,84]
When the antireflux barriers fail, the severity of tissue damage is determined by
epithelial resistance factors.[62] There are pre-epithelial, epithelial and intercellular protective
mechanisms. The epithelium is preceded by a mucous layer and an aqueous layer with high
bicarbonate content. Mucus resists penetration of large molecules such as pepsin, but it does
not prevent the ingress of acid. The aqueous layer is alkaline, and it buffers acid material. At
the cellular level, the cell membrane and intercellular junctions resist acid and pepsin.
Different tissues have variable epithelial resistance, with esophageal epithelium being more
resistant than respiratory epithelium. Even slight amount of GER in the hypopharynx or
larynx may cause significant injury, whereas reflux of the same degree in the distal esophagus
would be easily resisted. Posterior glottis is especially susceptible to the effect of EER. Cilia
sweeps refluxed material towards the posterior glottis, thereby resulting in longer contact with
refluxate and subsequently, injury to the epithelium.[49]
Pepsin the principal digestive enzyme has been found intracellularly in patients with
LPR, but not in the normal subjects. Pepsin combined with acid has been found to be the most
injurious agent with a significant association with laryngeal lesions.[6] A frequent association
being, a relative depletion of carbonicanhydrase, a natural buffer against injury.[85]
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Recent investigations suggest that vulnerable laryngeal tissues are protected from
reflux damage by the pH regulating effect of carbonic anhydrase in the mucosa of posterior
larynx.[86] Carbonic anhydrase catalyzes the hydration of carbon-di-oxide to produce
bicarbonate.[86] This protects tissues from the acid reflux. In the esophagus, there is active
production of bicarbonate in the extra cellular space that functions to neutralize refluxed
gastric acid.[87] It has been observed that carbonic anhydrase is absent in the laryngeal tissues
and there is no active pumping of bicarbonate in laryngeal epithelium in patients with
laryngopharyngeal reflux. Thus even if a patient does not have enough reflux to develop
esophagitis, he/she may develop symptomatic extraesophageal reflux.
3.3.6. Mechanisms of symptoms due to EER
Symptoms in otolaryngology patients are due to the reflux of esophageal contents into
the larynx and hypopharynx.[1]
Head and neck disorders associated with EER are postulated to occur via the following
mechanisms.
Direct mucosal damage and direct effect on mucociliary clearance from exposure to
gastric contents.
GER related distal esophageal damage results in vagally mediated, referred
symptomatology and laryngeal reflexes that are mediated by the stimulation of distal
esophageal afferents.[1,3,6,7,88] In fact, they may both play an essential part in
conjunction with each other.[89] Symptoms may arise either from direct mucosal injury
or because of damage to cilia, leading to mucus stasis and chronic throat clearing and
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chronic cough. Also the level of acidity corresponds to the degree of mucosal damage
where the most damaging pH is 0-4.[6] One single episode of reflux is enough for the
development of LPRD.[1]
Alteration of pH has a direct effect on mucociliary transport and may lead to increased
viscosity of the mucous blanket.[90] A reduction in mucociliary transport may decrease
resistance to infection and has been postulated to contribute to the pathogenesis of
subglottic stenosis.
Pepsin, found in gastric contents maximally active at pH 4.5, and its enzymatic
activity produces tissue damage. Healing of mucosal injuries take longer time in case
of acid and pepsin.[27]
Direct stimulation of sensory receptors in the larynx by aspirated or refluxed material
can result in reflexive vocal fold adduction or laryngospasm. This laryngeal chemoreflex
is associated with bradycardia, central apnea, and hypotension. Partial or complete
laryngospasm and cough that can also be triggered by reflux to the distal esophagus via a
vagally mediated reflex which can be associated with distal esophageal GER can be
associated with bronchospasm, increased secretions, tachycardia, and hypertension. These
reflexes have implications for respiratory manifestations of EER and in the mechanisms
involved in sudden infant death syndrome and recurrent laryngospasm.
3.3.7. Risk Factors
Certain habits and conditions that can contribute to both LPRD and classic GERD are
enumerated in Box 1:
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Risk factors in LPRD and classical GERD
• Drinking caffeinated beverages
• Eating before bedtime
• Eating foods that are high in fat, or spice
• Lying down after eating
• Obesity
• Alcohol use
• Smoking
• Wearing tight clothing
Box 1: Risk factors in LPRD and classical GERD
3.4. CLINICAL PRESENTATION
3.4.1 Symptoms
A good case history is very critical to both diagnosis and treatment of patients with
EER. The clinician must identify not only symptoms but also behavioral and medical risk
factors. It is also important for patient compliance to treatment, that the patient be actively
involved in the identification of the risk factors that he/she can modify. Common symptoms of
extra esophageal reflux (EER) are mentioned in Box 2 in increasing order of frequency.[91]
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Common symptoms of EER
Hoarseness/ dysphonia (episodic or chronic)
Globus sensation
Chronic throat clearing
Vocal fatigue
Voice breaks
Sore throat
Neck pain
Excessive throat mucus
Chronic or night time cough
Dysphagia
Odynophagia
Postnasal drip
Halitosis
Ear pain
Laryngospasm
Asthma exacerbation
Loss of upper singing range
Prolonged warmup time in singers
Heartburn/ regurgitation
Box 2: Common Symptoms of EER
The correlations between laryngeal findings, symptoms and pH monitoring have been
observed to be weak.[19,92,93] It has been reported that findings normally associated with LPR
may also be found among 86 % of healthy controls.[94] Pseudosulcus is proposed to be a better
predictor of LPR, which has a 70% sensitivity and 77% specificity.[95,96] Pseudosulcus is
caused by a bilateral infraglottic edema extending from the anterior commisure to the
posterior wall of the glottis, differentiating it from a true sulcus vocalis which is limited to the
membraneous parts of the vocal folds.
Review of literature
18 | P a g e
3.4.2. OTOLARYNGOLOGIC DISORDERS ASSOCIATED WITH EER
3.4.2.1. Chronic laryngitis
Laryngitis or laryngeal inflammation is relatively common, non specific and often
resolves spontaneously.[94] When laryngitis is persistent the underlying causative agent may
be allergy, infection, vocal trauma, postnasal drip or LPR. LPR may be suspected in the
presence of symptoms of hoarseness, globus, throat clearing, dysphagia, cough,
laryngospasm, throat pain and excessive mucus.[1,19]
Hanson and colleagues define chronic laryngitis as a 3 month or longer history of, hoarseness
that worsens with voice use; persistent or recurrent sore throat without throat infection;
sensation of post nasal drip; and throat clearing or cough in the absence of lower respiratory
tract or pulmonary disease.[28,68,84] Studies conducted in LPRD have reported that the sensation
of chronic postnasal drip is the most common and earliest manifestation of chronic irritative
laryngitis, the second and third being throat discomfort and dysphonia respectively. Ciliary
dysfunction in the posterior larynx and pharynx can cause a sensation of constant secretions
in the back of the throat.[49] With an empirical treatment comprising of a 6 week course of
PPI, significant improvement in the symptoms of laryngitis such as hoarseness, globus
pharyngeus, sore throat, heart burn, and coughing were observed.[97] Studies conducted in
LPRD have reported that the sensation of chronic postnasal drip is the most common and
earliest manifestation of chronic irritative laryngitis, the second and third being throat
discomfort and dysphonia respectively. Ciliary dysfunction in the posterior larynx and
pharynx can cause a sensation of constant secretions in the back of the throat.[49] With an
empirical treatment comprising of a 6 week course of PPI, significant improvement in the
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symptoms of laryngitis such as hoarseness, globus pharyngeus, sore throat, heart burn, and
coughing were observed.[97]
Fig 4: Chronic Laryngitis
3.4.2.2. Contact ulcer and laryngeal granuloma
Fig:5 Contact ulcer
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The etiologies for vocal process granuloma include EER, vocal misuse, intubation
trauma, smoking, chronic cough, chronic throat clearing, infection and allergies.[50]
3.4.2.3. Chronic cough
Chronic cough is defined as cough of more than 3 weeks duration. GERD together
with postnasal drip and asthma are responsible for over 90% of chronic cough cases, out of
which 10-30% could be directly related to GERD.[41,42]
3.4.3. Extraesophageal reflux and Dental erosions
The prevalence of dental erosion among individuals with GERD has been estimated to
be upto 20-55%, compared with a general population prevalence of 2-19%.[48] GERD patients,
diagnosed with pH-monitoring and endoscopy, were observed to have significantly more
dental erosions as compared with controls.[98]
3.4.4. Extraesophageal reflux and Asthma
Previous studies have proved a strong evidence linking asthma to GERD.[44,45] Acidity
in the trachea generates increased pulmonary resistance.[99,100] About 50-80% of the asthma
patients had GERD symptoms and among them up to 75% had a pathological acid
exposure.[44] The cause and effect relationship between asthma and reflux is however not clear
as both conditions may occur as the result of the other. Reflux may cause asthma through
micro aspirations into the bronchial tree or through a vagally mediated nerve reflex which
causes an asthmatic reaction. Adding to it, during an asthmatic attack the negative
intrathoracic pressure increases which might augment the reflux.[7]
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3.4.5. Extraesophageal reflux and head and neck cancer
Eventhough EER is not established as a cocarcinogen, it may play a vital role in the
development of head and neck squamous cell carcinoma.[33-35] Both surgical management as
well as radiation treatment of head and neck carcinoma can be complicated by the coexistence
of EER.[31]
Belafsky, Postma and Koufman developed the Reflux Symptom Index (RSI), a self
administered survey of nine questions used to assess patients with laryngopharyngeal reflux
disease.[15,101,102] They demonstrated that the index is reliable and that it provides reproducible
and valid findings.[15,101,102] Normative data gathered by these researchers support that an RSI
of more than 10 is significant. RSI of more than 10 is associated with a high likelihood of
positive results in a dual channel pH probe study.[15,95]
The Reflux Symptom Index was noted to show improvement before changes were
seen in the reflux finding score. A prospective study of 40 patients with documented EER by
dual pH probe studies and two month medical management with PPI showed a mean RSI of
19.3 at the initiation of treatment which improved to a mean of 13.9 after 2 months.[101]
3.4.6. REFLUX SYMPTOM INDEX
The Reflux symptom index is a self assessment questionnaire consisting of nine (9)
symptoms. The patients have to rank each symptom on the basis of how those problems have
affected him/her within the past month from a score 0 to 5 (0 – no problem to 5 – severe
problem).
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THE REFLUX SYMPTOM INDEX
Within the past month, how did the following problems affect you?
Rank them from (0 – no problem to 5 – severe problem)
1. Hoarseness or a problem with your voice
2. Clearing your throat
3. Excess mucous production in the throat or postnasal drip
4. Difficulty swallowing food, liquids, or pills
5. Coughing after you have eaten or after lying down
6. Breathing difficulty/ choking episodes
7. Troublesome/ annoying cough
8. Sensation of something sticking in your throat or a lump in your throat
9. Heartburn, chest pain, indigestion or stomach acid coming up
Box:3 The Reflux Symptom Index [102]
3.4.7. PHYSICAL EXAMINATION AND LARYNGEAL ENDOSCOPY
Several clues to EER can be observed by a thorough physical examination. The vital
factors in evaluation are the observations of the quality of the voice, frequent throat clearing,
cough or stridor, muscle tension in extralaryngeal musculature and general body habitus. The
evaluation of larynx can be done with indirect laryngoscopy along with rigid and/or flexible
laryngoscopy. For documenting treatment effects and for visualizing subtle signs associated
with acid reflux, videoendoscopy and stroboscopy are very useful.
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The majority of laryngeal findings seen in patients with chronic laryngitis associated
with EER are edematous changes, as opposed to erythematous changes, seen in posterior
larynx. Posterior laryngitis manifests as edema, loss of clear epithelial markings, and an
increased vascularity of the posterior commissure and arytenoids.[10,28,97] Chronic irritation can
result in thickening of the posterior laryngeal mucosa with hyperkeratosis which is also called
pachydermia laryngeus.[10,28] This posterior mucosal thickening with increased granularity and
rough cobble stone appearance has also been referred to as granular mucositis.[28] Increased
mucus formation and thickening, along with mucus stranding and pooling, may result from
chronic irritation and alterations of mucociliary flow.[10,65] Laryngeal ulcerations, granuloma
formation, scarring, and stenosis may indicate a higher grade of EER.[28,49,50,52]
Although it has been traditionally thought that erythema of the posterior larynx is the
key sign of EER, in reality it is the edema occurring as a consequence of acid reflux induced
trauma to the larynx, that is the clinical hallmark of EER.[28,49,93,103,104]
3.4.7.1. Findings
Posterior laryngitis, which is characterized by swollen arytenoid mucosa with inter
arytenoids mucosal hypertrophy or edema. This is due to the constant bathing of the
interarytenoid mucosa in the acid reflux. In severe cases the interarytenoid mucosa becomes
heaped up, so as to produce a protuberant mass. This is called interarytenoid pachydermia.
Generalized congestion and edema of the vocal cords make the ventricles shallow.
Ventricular mucosa appears congested. Edema of the undersurface of the cords can give rise
to pseudosulcus, which has been described as a common endoscopic finding in EER.[95,102,105]
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The pseudo sulcus is a shallow longitudinal cavity in the medial side of the vocal cord which
runs along the whole length of vocal cord including the cartilaginous part; whereas the true
sulcus never extends beyond the membranous part.[95,102,105] Other findings are thick
endolaryngeal mucosa and vocal process granuloma.
Fig 6: Laryngeal granuloma
pH measuring at the upper esophageal sphincter, laryngoscopy, esophagoscopy and
impedence testing are more definitive diagnostic tools according to literature. An empirical
course of medical therapy (employing the use of PPI) has been listed as a more practical
diagnostic tool.[21]
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3.4.8. REFLUX FINDING SCORE
Since there is an apparent known association between laryngopharyngeal reflux and
upper aerodigestive tract carcinoma, laryngeal examination should be performed in all cases
of suspected laryngopharyngeal reflux disease. [33-35]
In 2001 an endoscopic grading scale for laryngopharyngeal reflux disease was
developed by Belafsky and colleagues.[95] The sale was based on eight findings that have been
graded on the basis of severity on a scale with scores ranging from 0 – 26.
THE REFLUX FINDING SCORE
Subglottic edema 0 (Absent) 2 (Present)
Ventricular edema 0 (None) 2 (Partial) 4 (Complete)
Erythema/hyperemia 0 (None) 2 (Arytenoids only) 4 (Diffuse)
Vocal fold edema 0 (None) 1(Mild)
2
(Moderate) 3 (Severe) 4 (Polypoid)
Diffuse laryngeal
edema 0 (None)
1
(Mild)
2
(Moderate) 3 (Severe)
4
(Obstructing)
Posterior commisure
hypertrophy 0 (None)
1
(Mild)
2
(Moderate) 3 (Severe)
4
(Obstructing)
Granuloma/granulation
tissue 0 (Absent) 2 (Present)
Thick endolaryngeal
mucus 0 (Absent) 2 (Present)
Box 4: The Reflux Finding Score [95]
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3.4.9. VOICE ANALYSIS
Voice analysis comprises of measurements and analysis of parameters like jitter,
shimmer, and signal to noise ratios.[106] Previous studies by Shaw and Searl have depicted a
significant improvement in jitter, shimmer, and signal to noise ratios after anti secretory and
anti reflux treatment. However studies conducted by Hamdan and colleagues didn’t find any
change in acoustic parameters in patients undergoing medical treatment for EER.[107,108]
3.4.10. ESOPHAGOGRAM
Barium esophagogram is an inexpensive, convenient and noninvasive diagnostic tool
which can be used for diagnosing structural and functional abnormalities of the esophagus
like hiatal hernia, strictures, esophageal ring, diverticula, esophageal shortening, erosive
esophagitis, Barret’s esophagus, extrinsic compression, motility disorders, cricopharyngeal
spasm, possible malignancy and aspiration.[1,10,57,109,110]
The significance of performing Barium studies before planning an antireflux surgery
has been proven beyond doubt. Fluoroscopic evaluation has often been used to diagnose the
presence of reflux, and can be combined with provocative maneuvers, such as Valsalva’s
maneuver, water siphon test (the patient is asked to drink 60 ml water through a straw in
supine position followed by rolling from supine to the right lateral position). Barium
esophagogram can detect GER with a sensitivity that ranges between 20% and 60%, a
specificity of 64% to 90% and an accuracy of 69%.[57] Upon employing the water siphon test
the sensitivity of barium esophagogram in the evaluation of reflux, touches 70%, specificity
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reaches 74% and the positive predictive value of 80%.[110] The relevance of Barium
esophagography in patients with EER is less clear.
3.4.11. LARYNGEAL SENSORY TESTING
Laryngeal sensory testing alone, without evaluation of swallowing, can be used to
diagnose EER.[104] It is based on the concept that laryngeal sensory testing can quantify the
posterior laryngeal edema that results from acid reflux. Laryngeal adductor reflex, which is a
brainstem mediated, airway protective reflex that can be induced by administering a pressure
and duration controlled pulse of air to the arytenoids epithelium. The practical way to explain
laryngeal sensory testing is that a stronger air pulse pressure is required to cause indentation in
an edematous arytenoid compared to what is required by a non edematous arytenoids
epithelium.
3.4.12. ESOPHAGEAL ENDOSCOPY – TRANSNASAL AND TRANSORAL
ESOPHAGOSCOPY
The association between esophageal malignancy and reflux is well established, hence
the symptoms related to larynx and pharynx may be more predictive of the presence of
esophageal carcinoma than the classic gastro esophageal reflux disease.[33-35,111] Hence
esophageal endoscopy is inevitable while evaluating the presence or absence of carcinomas.
[33-35,111-116] The normal stratified squamous epithelium of the distal esophagus is replaced by
columnar epithelium which is typically the epithelium lining the stomach in patients with acid
induced reflux esophagitis.[117] This condition is called as Barret’s esophagus.[117] GERD was
linked to Barret’s esophagus and esophageal adenocarcinoma.[112-117]
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Unlike laryngeal squamous cell carcinoma, which causes symptoms like hoarseness of
voice, cough, foreign body sensation in throat even when a vocal fold lesion is miniscule,
esophageal adenocarcinoma generally manifests when the esophageal lesion is so large that
the patient presents with dysphagia. As a result of which, most esophageal cancers are
detected at an advanced stage with a 5-year survival rate of less than 10% for a case of
symptomatic esophageal adenocarcinoma.[118,119] In esophageal carcinoma, laryngopharyngeal
symptoms like cough and hoarsness are better predictors than heartburn and regurgitation.
Therefore an endoscopic examination of the esophagus is indicated in patients in whom
symptoms of laryngopharyngeal reflux disease persists, despite the administration of antacids.
This makes way for the early detection of esophageal carcinoma, if present.[112-115] Esophageal
endoscopy is indicated whenever a malignancy of the digestive tract is suspected, such as in
patients with significant dysphagia, weight loss or constitutional symptoms. These clinical
features point towards the presence of a carcinoma.
The esophagus can be examined endoscopically through a transoral approach or by a
transnasal approach. The transoral route can either be performed in an operating room with a
rigid esophagoscope with the patient under general anaesthesia or using a flexible
esophagoscope employing an endoscopy suite with the patient either being maintained in a
conscious state or under sedation, the sedative being administered intravenously.
Esophagoscopy can be performed transnasally using an ultra thin caliber endoscope which is
introduced through a topically anaesthetized nasal cavity (Trans Nasal Endoscopy - TNE).[120]
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3.4.13. RADIONUCLIDE SCANNING
Radionuclide scanning is a simple test which uses a gamma camera. GER index is
calculated from the radioactive refluxate in the esophagus. Sensitivity of radionuclide
scanning is less than that of esophageal endoscopy.[103]
3.4.14. MANOMETRY
The importance of the use of manometric evaluation in patients with GERD is well
documented in literature. The significance of esophageal dysmotility in patients with EER is
well documented.[80] Cervical symptoms of EER is associated with low LES pressure.[64]
Transient relaxation of the LES plays an important role in the pathogenesis of EER.[57]
Esophageal manometric evaluation is essential for planning an antireflux surgery.[109] Though
manometry is useful in certain subsets of patients with EER, it might not prove handy as a
test for diagnosing the same. Manometry might not accurately assess patients for the absence
of relaxation of the LES and, therefore EER.[57]
3.4.15. pH PROBE MONITORING
The gold standard for the diagnosis of GERD and EER is continuous pH monitoring
studies.[1,57,111] A catheter is introduced transnasally into the esophagus with a probe or
detector just above the LES and another at or above the UES. Probes that sense pH changes
can be placed in different locations in esophagus, hypopharynx and pharynx. The location of
the probes can be verified using endoscopy, fluoroscopy or manometry. It is important to add
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a second probe above the UES, if extraesophageal symptoms of EER are being identified. The
test is limited by patient tolerance to the catheter being placed. It is left to remain from the
nose to the stomach for 24 hours. The disadvantages of the above said test are, it is an
invasive test, its sensitivity is not more than 75% to 80%.[117] False negative results may
approach 50%.[121] Small variations in the technique for placement of probe or calibration can
significantly affect accuracy.[118] Documentation of patient position (supine/ upright), diet and
symptoms are also important factors determining the outcome of the study.[118] The patient
has to maintain his/her usual dietary and smoking habits and activity level during the course
of the study.[118,122,123]
Figure 7: Double pH probe Monitoring
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The advantage of pH capsule is that it is more comfortable for the patient, more
reliable than the catheter-based technique since it can provide information about esophageal
acid exposure for 24 – 48 hours, more time duration of pH data and hence the diagnosis can
be more securely and precisely made.[126]
3.4.16. PEPSIN DETECTION
Pepsin which is active at pH level of up to 5, has been proven to play a critical role in
the pathogenesis of tissue damage.[1] Pepsin is a large bi-lobed molecule of an aspartic
proteinase, which is present in all vertebrates subjected to analysis.[127] It belongs to a family
of isoenzymes which are structurally similar.[127] The largest of these isoenzymes (at least
70%) is pepsin 3B complex.[127] Maximal pepsin activity is seen between pH of 6.5 and is not
completely denatured until pH 7.8.[128] Hence gastric refluxate, which encompasses a wide
range of pH, might cause damage even when there is little acid. The enzymatic activity of
pepsin is dependent on pH, and it is activated in an acidic pH.[62] Detection of pepsin in the
gastric refluxate can be used as a marker for gastro esophageal reflux as it is a major
component of gastric refluxate.[127] Pepsin analysis by ELISA assay using polyclonal pepsin
antibodies is historical. Even though ELISA method is sensitive, it is prone to errors due to its
complexity. An analysis can take 24 to 36 hours keeping in mind the fact that the polyclonal
antibodies used are non-specific to pepsin. With the development of unique and highly
specific monoclonal antibodies to human pepsin 3, this approach has now been superseded.
The development of Lateral flow device (LFD) has revolutionized the detection of pepsin in
clinical samples using two monoclonal pepsin antibodies for capturing and detecting pepsin.
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LFD is a non invasive test developed to detect salivary pepsin in symptomatic
individuals. LFD can be done to detect pepsin in exhaled breath condensate, bronchoalveolar
lavage fluid, sputum and middle ear effusions. To the well of each LFD 75 mcl of sample
consisting of 25 mcl clinical sample with a specific buffer were added. Beneath the well of
LFD is a nitrocellulose membrane pretreated with
1. The capture monoclonal pepsin antibody (test line),
2. Latex-bead labeled detection monoclonal pepsin antibody and
3. A control secondary antibody (control line).
Figure 8: Procedure of LFD
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Figure 9: Lateral Flow Device
Pepsin is detected first if present in the clinical sample. Then it passes along the nitrocellulose
membrane where the monoclonal antibodies are captured at the T-line. Following sample
application the colour development at the T-line (pepsin) and the C – line (control) will be
clearly visible within five minutes with an accurate detection level as low as 16ng/ml
pepsin.[127] The analysis of clinical samples has demonstrated a sensitivity and specificity of
88% and 87% respectively. Using an electronic reader, reflectance value for the T and C line
of each LFD is measured for differentiation of clinical sample concentrations and
performance of the LFD. The sensitivity of LFD is slightly lower than the conventional
ELISA.[127] Non invasive LFD pepsin test is a powerful diagnostic tool in the armoury of
clinician for detecting pepsin related diseases and reflux diseases.[27]
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3.4.17. IMPEDANCE TESTING
The changes in the ionic conduction of the pharyngeal or esophageal lumen are
detected by impedance testing.[129] With impedance testing solid, liquid and gas reflux can be
detected based on the electrical conductivity of what is travelling within the esophagus.
Impedance testing is an important diagnostic tool for measuring nonacidic reflux or events
with minor changes in pH, as in case of non-acidic belch, where reflux event may occur
without the pH probe noting it.
The introduction of multichannel intraluminal impedance (MII) technology using a pH
sensor (MII-pH) allows the detection of nonacidic gastroesophageal reflux. MII testing also
detects the direction of material flow, i.e. antegrade/retrograde. Both acidic and nonacidic
reflux events can be detected by adding pH monitoring to the impedance analysis.[130] In EER,
it is believed that often nonacid reflux events are responsible for persistent symptoms despite
aggressive antiacid pharmacotherapy.[131,132] MII-pH will most likely have a significant and
growing role in diagnosing patients with EER, because studies have shown that during
prolonged monitoring of pH levels, typical GER symptoms are related more to acid reflux
events than to nonacid reflux events. Those with persistant symptoms during acid-suppressive
therapy are often related to nonacid reflux events.[131,132]
The therapeutic options for the nonacid component of the refluxate are varied and, in
addition to acid suppression, prokinetics like baclofen and mucosal protective agents like
alginate should be added.
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3.4.18. REFLUX AREA INDEX (RAI)
Recent developments in pH diagnostics are - the use of reflux area index (RAI) which
is calculated from the number and duration of proximal reflux events, both at pH 4 and 5.[133]
3.5. TREATMENT
Reflux diseases can be managed by medical or surgical modalities
3.5.1. BEHAVIORAL MODIFICATION
Behavioral changes that are aimed at reducing episodes of reflux may be critical to the
successful management of EER. The recommended modifications include avoidance of eating
or drinking 3 hours before lying down; avoidance of tobacco products, alcohol, fried foods,
fatty foods, chocolate, caffeine, spicy food, and peppermints; avoidance of tight fitting
clothing and elevation of the head end of the bed by 6-8 inches.[28,70,107] The extent of
symptomatic improvement correlates positively with both medical therapy and behavioral
modification. Avoidance of solid foods or liquids before bed time and the elevation of head
end of the bed showed significant reduction in the occurrence of symptoms.[18] Cigarette
smoke promotes reflux by its effect on LES; it might also alter the regulatory protection of the
UES and the glottis itself and subsequently make the smoker’s larynx and upper airway more
susceptible to reflux injury. The acid exposure to lower esophagus is reduced with reduction
in fat intake and smoking, head end elevation while sleeping and allowing atleast 3 hours
between eating and lying down.[70] Chewing gum for one hour after food intake showed a
reduced acid contact time and raised esophageal and pharyngeal pH.[134,135] Walking for one
hour postprandially can mildly reduce the acid reflux.[134] Despite the clear benefit from
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behavioral adjustments, these important measures are not usually sufficient in most of the
patients, either due to the severity of the clinical issue or patient’s non compliance.
3.5.2. MEDICAL TREATMENT
Proton pump inhibitors (PPI) are the mainstay of treatment for reflux diseases.
3.5.2.1. Antacid
Aluminium and magnesium based, bicarbonate based and bismuth based antacids have
proven to be beneficial and cost effective. These medicines are usually procured over the
counter by the patient and can alleviate traditional GERD symptoms such as heartburn and
regurgitation. These substances neutralize the pH of the stomach acid, and can thereby prevent
the tissue damage caused by bile salts and deactivate pepsin at a higher pH.[136] Antacids have
been shown to increase LES resting pressure.[24] Antacids may be used as a first-line therapy
in patients with minor EER or as an adjunct to other treatment modalities.[137]
3.5.2.2. H2 blockers
H2 blockers act at the histamine type 2 receptor by competitive binding, and thereby
reduce the gastric acid secretion along with pepsin production.[65,136] H2 blockers may be used
as a first line therapy in patients with minor EER, as adjunctive therapy, or as step down
therapy to wean off patients from PPIs.[137,138]
3.5.2.3. Proton Pump Inhibitors
PPI’s act against the enzyme hydrogen potassium adenosine triphospatase in the
parietal cell, thereby blocking the final step of gastric acid production.[65] These drugs are
more effective than H2 antagonist in the long term reduction of basal and stimulated levels of
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gastric acid production.[139] There is a significant number of patients on PPI therapy for
chronic laryngitis showing a relative PPI resistance.[140] The PPI’s include pantoprazole,
omeprazole, lansoprazole, rabeprazole, and esomeprazole.
3.5.2.4. Promotility agents
Metoclopramide, a dopamine antagonist, is effective against GERD. It raises LES
pressure, improves gastric emptying and might improve esophageal clearance.[65] Patients
with diabetes mellitus, dystrophia myotonica, and anorexia nervosa may have significantly
delayed gastric emptying and thus may benefit from prokinetic agents.[99] Erythromycin can
act as a motilin agonist, and may be used as a prokinetic agent.[100]
3.5.2.5. Other medical therapy
Sucralfate has been shown to enhance mucosal resistance to trauma. It is effective in
promoting healing of duodenal ulcers, and protects the esophageal mucosa against injury from
gastric acid.[65] Sucralfate is a salt of sucrose, and is usually well tolerated by patients. Its
effectiveness in the treatment of EER is not well elucidated. Bethanechol is an anticholinergic
agent that has been shown to increase LES pressure, decrease GER, and improve salivary
flow.[65]
3.5.3. SURGICAL TREATMENT
Antireflux surgery involves replacing the LES into the abdomen and then augmenting
the LES as an antireflux barrier. The Nissen fundoplication involves the use of a 360 degree
wrap of the gastric fundus around the intra abdominal esophagus.[109] Ten year success rate for
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the use of this procedure in treatment of GERD has been quoted to be around 90%, with a
mortality rate of 1%.[109] Fundoplication can be performed either by an open or by employing
a laproscopic approach. Complication of fundoplication are rare and include bleeding, the
need for splenectomy, slipping of the fundoplication in to the chest, dysphagia, bloating,
diarrhea, gastric ulceration and pneumothorax.
REVIEW OF RECENT STUDIES
Several studies have been conducted on, ‘the effect of proton pump inhibitors in
laryngopharyngeal reflux disorder’ worldwide. Proton pump inhibitors have been used in the
treatment of laryngopharyngeal reflux since long.
A study on reflux symptom index & refl l gic practice
was done by Walter Habermann et al, Vienna School of Evidence based Medicine, Austria. In
this study, the effect of proton pump inhibitors on the laryngopharyngeal reflux disease was
analysed and found to be useful prognostic tool.[27]
Habermann W, et al conducted an open, multicenter prospective, longitudinal cohort
study on Reflux symptom index and Reflux finding score in 1044 patients over a period of 20
months. Median total score of RSI before therapy was 12 and it came down to 3 (P<0.001).
Median total score of RFS before therapy was 16 and post therapy was 6 (P<0.001).[4]
Powell J and Cocks HC conducted a study regarding the mucosal changes in
laryngopharyngeal reflux disease its prevalence, sensitivity, specificity and assessment. The
study showed that one or more laryngopharyngeal mucosal signs associated with LPR were
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identified in 64% to 93% of healthy volunteers and in 17% to 85% of gastroesophageal reflux
disease sufferers. The use of multiple mucosal signs might improve detection
of reflux sufferers from asymptomatic controls.[8]
Kondo Y and colleagues studied about edema of the interarytenoid mucosa seen on
endoscopy and its relation to endoscopy positive esophagitis (EE). The study showed that
frequency scale for the symptoms of gastroesophageal reflux disease (FSSG) score had no
significant relationship with EE. There was no relationship between patient’s characteristics
and EE, regardless of its severity.[11]
Matoo O and colleagues in 2012 did a prospective study analyzing various non-
surgical treatment modalities for Laryngopharyngeal reflux disorder which showed twice
daily dosing of esomeprazole and domperidone with life style modification proved
effective.[12]
Park W, Hicks DM, Khandwala F, Richter JE, Abelson TI, Milstein C, et al in 2005
conducted a prospective cohort study evaluating the optimal dose of proton pump inhibitor
therapy & pre therapy predictors of response in 85 patients. In this study patients diagnosed
with laryngopharyngeal reflux based on ENT symptoms and laryngoscopic findings were
enrolled and it was found that a twice daily dose was more effective than once daily
regimen.[22]
Review of literature
40 | P a g e
Lieder A and Issing W in December 2011 conducted a study entitled ‘Treatment for
resilient cough owing to laryngopharyngeal reflux with a combination of proton pump
inhibitor and Gaviscon® Advance: how we do it?’ It was observed that there was a significant
better improvement in hoarseness and throat clearing with Gaviscon, an alginate suspension
with Proton pump inhibitors.[9]
The study by Hanson DG, Kamel PL, Kahrilas PJ in 1995 regarding the Outcomes of
antireflux therapy for the treatment of chronic laryngitis, showed a response of 77% in those
treated with famotidine 20mg at bedtime in addition to antireflux precautions.[28]
A study conducted by Wolfgang Issing in UK, clarified that a significant improvement
in hoarseness and throat clearing in the proton pump inhibitor group than the placebo. They
were still unclear regarding the therapeutic benefit of proton pump inhibitors in the treatment
of laryngopharyngeal reflux. They recommended future studies should include larger study
populations, instructions on how to take the medication and provision of an accepted
diagnostic tool to confirm reflux.[27]
A retrospective study was conducted by Jayakumar Menon in 2009 regarding the
throat manifestations of gastroesophageal reflux disorder. He concluded that
laryngopharyngeal reflux disorder was a fairly common condition and laryngopharyngeal
reflux had a very high association with vocal cord malignancy, suggesting the possibility that
it is causative factor in its pathogenesis.[27]
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Koufman was the first to clearly distinguish laryngopharyngeal reflux from
gastroesophageal reflux disorder. He noted that in a combined reported series of 899 patients,
throat clearing was a complaint of 87% of larygopharyngeal reflux patients was 3% of
patients with gastroesophageal reflux disorder. Only 20% of laryngoesophageal reflux patients
complained of heartburn compared to 83% of those with gastroesophageal reflux disorder.
According to Koufman larygoesophageal reflux was the first among the top 10 causes of non-
pulmonary chronic cough, this was caused by posterior laryngeal inflammation (reflux
laryngitis) leading to stimulation of supraglotic laryngeal receptors and endolaryngeal
aspirations of gastric contents.[1]
An international survey conducted by members of American Bronchoesophagological
Association revealed that the most common laryngoesophageal reflux symptoms were Throat
clearing (98%), Persistent cough (97%), Globus pharyngeus (95%) and Hoarseness (95%).[141]
Unfortunately, accurate estimates of the incidence of LPR were not available.
Koufman & colleagues reported that 50% of all patients presenting to their center with
laryngeal & voice disorders had LPR, as documented by dual pH probe studies.[13]
In a retrospective study conducted by Rival R, that reviewed patients presenting with
common cervical symptoms, it was demonstrated that 73% of patients had GERD and
symptomatic relief with antireflux medication was 84%.[64]
A survey of members of the American Bronchoesophagological Association reported
that 75% of their respondents claimed that less than 50% of their patients’ had LPR related
disorders, and there was a lack of consensus regarding evaluation and treatment
modalities.[141]
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Studies were also conducted regarding the association of esophageal acid clearance
and LPR. Knight and colleagues studied 100 subjects with EER & noted that 52% had
ineffective esophageal motility.[80]
In another study conducted by Ulualp SO, Toohill RJ, primary esophageal peristalsis
in patients with GERD & posterior laryngitis was similar to that in normal controls. In
patients with GERD, secondary esophageal peristalsis was noted to be decreased in
comparison with that in controls.[70]
Hanson & Jiang postulated that the posterior glottis is especially susceptible to the
effect of EER. They postulated that the cilia beat material to the posterior glottis, resulting in
longer contact with refluxate and thereby more injury to this epithelium.[49]
Direct stimulation of sensory receptors in the larynx by aspirated or refluxed material
can result in refluxive vocal fold adduction. Studies regarding this chemo reflux was done by
Bauman NM, Sandler AD, Schmidt C.[53]
In a retrospective review of 216 patients with cervical symptoms that were believed to
be associated with EER, Rival and associates found that the most common complaint was
cervical dysphagia (33%), followed by globus (19%), sorethroat (17%), and chronic throat
clearing (14%). The researchers found that 66% of their patients complained of classic
symptoms of GERD, such as acid regurgitation and heartburn.[64]
Fraser & coworkers prospectively reviewed patients with symptoms believed to be
associated with EER in whom pH probe results were positive and found out that cough and
hoarseness were the most common symptoms. In their study 77% of patients also complained
of classic symptoms of GERD.[142]
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In a survey conducted by American Broncho-Esophagial Association members,
respondents believed that most common symptoms related to EER were throat clearing,
persistent cough, heartburn/dyspnea, globus sensation, and voice quality change.[141] The
importance and relevance of these findings were supported by the work of Reavis and
associates, who showed that laryngopharyngeal manifestations of acid reflux , specifically
cough and hoarseness, better predicted the presence of adenocarcinoma of esophagus than
classic GERD symptoms such as heartburn and regurgitation.[17]
Belafsky and colleagues developed reflux symptom index (RSI), a self-administered
survey of nine questions used to assess patients with EER. They demonstrated that the index
was reliable and it provided reproducible and valid findings. Normative data gathered by these
researchers support that an RSI of more than 10 was associated with a high likelihood of
positive results of dual channel pH probe study. They prospectively evaluated 40 patients with
EER (as documented by dual pH probe studies) and 2 months of medical management. The
RSI showed improvement before changes were seen in physical findings. The mean RSI at
initiation of the study was 19.3, which improved to a mean of 13.9 within 2 months
treatment.[102]
A study conducted by Habermann and colleagues, reviewing the endoscopic findings
in 29 patients with chronic dysphonia and chronic laryngitis, showed that edema of the
posterior glottis mucosa was the most common finding. The researchers noted significant
improvement in the edema of posterior glottis mucosa with therapy. Alterations of the true
vocal fold mucosa and false vocal folds were also noted to improve with treatment.[97]
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Shaw and Searl assessed 96 patients who had symptoms suggestive of EER and noted
that posterior glottic edema and nodularity were the most severe and frequent findings. Only
47% of patients were found to have ulceration, and 3 patients were found to have
granulomas.[107]
Branski and coworkers performed a prospective, randomized, blinded study to assess
the reliability of laryngoscopic evaluation of patients with EER. They found that both intra-
rater reliability and inter-rater reliability were poor; raters had a poor agreement regarding
severity of endoscopic findings for LPR. The investigators concluded that using laryngoscopic
findings alone for diagnosis EER was highly subjective.[93]
Belafsky and colleagues, evaluated pseudosulcus in 30 patients with EER (i.e., with
positive pH probe results) and 30 control and found pseudosulcus in 70% patients with EER
documented EER. The sensitivity and specificity of pseudosulcus were estimated to be
70% and 77%, respectively.[95]
Hickson and colleagues prospectively assessed, with dual channel pH probe studies 20
patients, in whom endoscopic evaluation had confirmed pseudosulcus; EER was identified
with positive pH probe results in 18 out of 20 patients. These researchers estimated that the
positive predictive value for pseudosulcus for EER was 90%.[105]
developed an endoscopic grading scale for EER. The Reflux
Finding Score(RFS) consisting of eight findings, seven of which were related to edematous
changes in the endolaryn rynx, graded severity in a
score from 0 to 28. The researchers reported that an RFS of more than 7 was associated with a
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high likelihood that, in 40 control
subject and 40 patients with clinical history positive for EER and pH studies. This review
showed excellent interobserver and intraobserver r
control subjects was 52 whereas the mean RFS at entry for the EER group was 11.5. An
individual with an RFS of more than 7 was noted to have EER with 95%certainty.[95]
Beaver and Colleagues conducted a prospective study of the videostroboscopic images
of 49 patients diagnosed with reflux disease on the basis of two or more
symptoms (i.e., throat clearing, hoarseness, cough, globus, or excessive mucous) along with
tis. Subjects were evaluated before and after 6 weeks of
high dose proton pump inhibitor (PPI) therapy. Ten controls without any symptoms of EER
random order, gave each a score using the laryngopharyngeal reflux disease index. The mean
index value for patients was significantly higher than that in controls (9.50 vs. 2.92
respectively), and post treatment mean scores were significantly lower than pretreatment
scores (7.35 vs. 9.50, respectively). The most useful items on the scoring system were
ttic edema and erythema, and subglottic edema and
erythema.[103]
Voice quality studies were also conducted on the effect of antireflux treatment on
EER. Hanson and colleagues reviewed voice quality and measures of jitter, shimmer and
signal to noise ratios in 16 patients undergoing treatment for chronic posterior laryngitis.
Perceptual analysis did not show correlation with acoustic measures, and did not show
significant changes with treatment. The investigators did demonstrate that measures of jitter,
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shimmer and signal to noise ratio improved significantly with antisecretory and antireflux
treatment of chronic posterior laryngitis.[106]
Shaw and Searl noted significant improvement in measurements of jitter, shimmer,
habitual frequency, and frequency range with anti reflux treatment in their patients who had a
pretreatment complaint of hoarseness.[107]
A comparitive study, between barium esophagogram and esophageal pH probe study
was conducted by Thompson and associates. They assessed 117 patients with clinical GERD
and compared the results of esophageal pH probe studies with those of barium
esophagograms. They demonstrated that barium studies showed unprovoked reflux in 26% of
subjects with positive pH probe study results.[110]
Knights and co-workers documented the significance of esophageal dysmotility in
patients with EER. These investigators used manometric studies of 100 patients with EER to
show that 29% had normal motility, 48% had ineffective motility, 10% had a hypertensive
lower esophageal sphincter, 9% had nutcracker esophagus, and 4% had esophageal
achalasa.[77]
Dual pH probe studies conducted by Kaufman and colleagues showed 11% of patients
had a positive upper probe result with normal esophageal pH probe acid exposure time.[56]
Little & associates demonstrated, the importance of proximal probe in children and
noted that 46% (78 out of 163) of subjects were found to have EER by proximal probe in spite
of negative lower esophageal probe results. But Hansen & colleagues stated that the false
negative rate of dual probe studies might approach 50%. It was an invasive test and its
sensitivity is no more than 75% to 80%.[143]
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A study regarding the behaviour modification and its effect on EER has been
evaluated by Giacchi & Associates and found that compliance with behaviour modification
varied widely.[18]
Studies regarding the surgical treatment and its effect on EER were done by Lindstrom
& Associates which was a retrospective study, patients were reviewed with EER who
lication and found that 25 out of 29 patients had near total
symptomatic relief and were not taking any antireflex medications.[144]
Studies were also conducted to find out the relevance of barium esophagography in
patients with EER. In Toohill and Kuhn's series of 286 patients with dysphonia and various
laryngeal disorders, 79.9% had abnormal esophagogram findings.[10] Rival and colleagues
showed that 22 out of 73 patients with EER symptoms had normal barium swallow study
results, with 50% of these patients demonstrating EER on subsequent diagnostic testing.[64]
Giacchi and colleagues reviewed 28 patients with otolaryngologic manifestations of EER,
reporting that barium esophagogram revealed reflux in 45% of patients and that 50% had
normal findings.[18]
Two studies have demonstrated that laryngeal sensory testing can be used to qualify
the edema due to LPR. In one study 76 patients were prospectively evaluated to determine the
relationship between double-probe pH testing results laryngopharyngeal sensory testing
results, and transnasal flexible laryngoscopy (TFL) findings. All 76 patients underwent dual
channel 24-hour pH testing after 7 day with no PPI treatment, sensory
testing, and TFL performed by otolar
and laryngopharyngeal sensory testing results. There were three patient groups: Group A (the
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study group) consisted of patients with GERD who had LPR symptoms; Group B (GERD
controls) had GERD but no LPR symptoms; and Group C (normal) had no GERD and no LPR
symptoms. GERD was defined as a distal probe pH of less than 4 more than 5.4% of the time
during a 24 hour period. Patients with GERD and LPR symptoms (group A) had significantly
higher posterior laryngopharyngeal sensory thresholds than both patients with GERD but no
LPR symptoms and controls with no GERD and no LPR symptoms. Sensitivity of blinded
TFL findings versus dual-charnel 24 hour pH testing was 50%, and specificity was 83%.
However adding the finding of air
sensory testing increased the sensitivity to 88% and also specificity to 88%. This study
showed that LPR is associated with a posterior laryngeal sensory neuropathy with impairment
of laryngeal adductor reflex. The investigators reasoned that because a greater air pulse
strength was required to elicit the laryngeal adductor reflux in the patients with documented
acid reflux than in the controls, this finding effectively represented an alteration in laryngeal
sensory nerve function, hence they used the term “neuropathy”. Furthermore, the combination
of sensory testing, specifically a sensory defect greater than 5 mm Hg air pulse pressure and
TFL findings were essentially as sensitive and specific as 24 hour diagnosis of
acid reflux disease.[145]
Another key prospective study compared 15 patients who had chronic cough (no
asthma, no rhinitis) and 24 hour pH probe- documented GERD with 10 healthy controls. The
patients in both study groups had laryngeal sensory testing before and after laryngopharyngeal
infusions of normal saline and 0.1N hydrochloric acid(on separate days). The baseline
threshold for electing the laryngeal adductor reflex was significantly greater for both, patients
with pH probe documented acid reflux disease and patients and controls exposed to 0.1N
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HCL. The researchers concluded that the sensory integrity of the laryngopharynx is
significantly impaired after exposure to even small amounts of acid and that patients with
cough and proven GERD have reduced laryngopharyngeal sensitivity compared to healthy
controls; which could result in a higher risk of aspiration.[146]
In patients with GERD, esophagogastroduodenoscopy may be valuable in the search
for esophageal mucosal irritation and to rule out Barret's esophagus. Deveney and colleagues
inflammatory lesions and found that three
out of seven (43%) had esophagitis although none had Barret's esophagus.[147]
Tauber and associates prospectively evaluated the incidence of gastroenterologic
diseases in patients presenting with non-specific laryngopharyngeal symptoms that were
believed to be associated with EER. Thirty such patients refused pH probe studies and were
evaluated with , gastric culture was positive for Helicobacter
pylori in 23% and 73% had some form of gastrointestinal disease diagnosed by EGD/biopsy.
Medical therapy for reflux and H.pylori (in patients found to have the infection) resulted in a
90% therapeutic success rate for symptom resolution.[148]
McMurray and colleagues, who studied paediatric patients who were undergoing
evaluation for airway reconstruction, found that significant reflux as demonstrated by the
lower esophageal pH probe did not correlate with positive esophageal endoscopic findings or
biopsy proven inflammation of the upper or lower esophagus. A weak correlation was seen
between laryngoscopic findings of EER and postcricoid biopsy findings.[56]
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Wright and Rhodes reviewed 145 patients with EER symptoms who underwent
laproscopic hill repair and found statistically significant improvement in EER symptoms post
operatively.[31]
Hanson and Jiang studied 182 patients with chronic laryngitis associated with EER
and found that treatment within 12 weeks.
51% (93 patents) showed response to nocturnal antireflux management alone; 48 patents
required the addition of a H2 blocker at night, and 34 required the addition of 20 mg of
omeprazole at night. 7 patients in the study required higher dosages of omeprazole, all of
whom were noted to have severe laryngeal changes at their pretreatment examinations.
Symptomatic relapse was common with the discontinuation of the therapy.[49]
Habermann and colleagues showed that hoarseness, globus
heartburn, and coughing were symptoms in patients with chronic laryngitis that showed
significant improvement with an empiric 6-week course of a PPI.[97]
Association with laryngeal and pharyngeal squamous cell carcinoma were evaluated
by Copper and colleagues. They did prospective evaluation of 24 patients with laryngeal and
pharyngeal squamous cell carcinoma and 10 patients who had previously received
radiotherapy, all of whom had undergone 24-hour dual pH probe testing before treatment. In
11 of the 24 patients, pathologic reflux was confirmed by both probes and only 4 patients
(17%) had negative results for both probes. In the irradiated patients, pathologic reflux was
documented by the upper probe in 60%, by the lower probe in 70% and by both probes in
40%, a high incidence of LPR was seen in patients with premalignant and early glottic
carcinomas with 85% having positive pH probe results. No significant condition with severity
of reflux or histologic stage was seen.[31]
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Sung and colleagues conducted study on effect of bile acid on cultured human
pharyngeal cells. Bile acid was known to be associated with tumour formation in the
esophagus through the over expression of cyclooxygenase-2.[34]
Only few perfect studies have so far been conducted on the effect of proton pump
reflux finding score by endoscopy. Most of the studies were
Reflux Finding Score were easy to
administer in the routine care of patients suspected of having laryngopharyngeal reflux
disease.
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4. MATERIALS AND METHODS:
4.1. STUDY DESIGN:
This was a prospective study with quasi experimental design to know the effect of
proton pump inhibitors on the reflux symptom score and reflux finding score in
laryngopharyngeal reflux disease.
4.2. STUDY POPULATION AND SETTING:
85 patients between the age group of 18 to 80 years, who came to the outpatient
department of Otorhinolaryngology with symptoms suggestive of laryngopharyngeal reflux
disease, in Sree Mookambika Institute of Medical Science, Kulasekharam, Kanyakumari
District were included in the study
4.3. PERIOD OF STUDY
From July 2013 to August 2014
4.4. GROUPS:
Subjects were evaluated as 2 (two) groups.
4.4.1. Group 1: Pretreatment group - Patients with Laryngopharyngeal reflux disease,
who fulfill the criteria of inclusion and exclusion, were included in the study and their reflux
symptom index and reflux finding score were studied.
4.4.2. Group 2: Posttreatment Group – Pretreatment group was again studied for reflux
symptom score and reflux finding score.
The Pretreatment group acts as control for posttreatment group.
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4.5. METHODOLOGY
4.5.1. Equipments used:
Flexible Nasopharyngo Laryngoscope – Karl Storz
4.5.2. Procedure:
Those patients who fulfilled the inclusion and exclusion criteria were enrolled and
subjected to endoscopic examination. Patients were evaluated using Reflux Symptom
Index, a set of nine self-assessment questions that are graded from 0 to 5 (with a total
score of 0 – 45) according to severity and those who were having a score of 3 or more in
any of the symptom scores were selected for endoscopic examination for the assessment
of reflux finding score after getting consent.
2 drops each of Nasal decongestants (Xylometazoline) and 4% Xylocaine was
instilled in the patient’s nostril for nasal decongestion and local anaesthesia.
Xylocaine viscous 10 ml was administered orally to the patient. The patient was
advised not to swallow and retain the preparation for 2 minutes, to anaesthetize the
throat.
Flexible nasopharyngolaryngoscope was introduced with proper lubrication through
nostril and guided to the laryngopharnx and the larynx was assessed.
Patients whose reflux finding scores were above 7, were given Proton pump
inhibitors (Pantoprazole 40 mg twice daily 1 hour before food)8 for a duration of 6
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weeks and were evaluated again with Reflux Symptom Index and endoscopic
examination.
Endoscopic examination was done by the study investigator and confirmed by an
expert who was not below the post of an Assistant professor. We recorded the Reflux
Symptom Index and Reflux Finding Score on the proforma along with a set of questions
regarding their dietary, history and habits.
Figure 10. Diagramatic representation of flexible Nasopharyngolaryngoscopy
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Those patients whose reflux finding scores were above 7 were given 6 weeks of
Proton pump inhibitors in the prescribed dose (Pantoprazole 40 mg twice daily).
In the follow up, patients were again assessed with Reflux symptom index
questionnaire and a repeat nasopharyngolaryngoscopy was done and Reflux Finding
Score recorded.
4.6. SAMPLE SIZE:
Sample size of each group:
41
Total sample size of the study:
82
4.6.1. Scientific basis of sample size used in the study:[143]
N = Total sample size
(95% Confidence Interval) = 2.576 (Standard Normal Deviate corresponding to selected
significance criteria )
(0.95) = 1.645 (Standard normal Deviate Corresponding to selected Statistical power)
- Assumed standard deviation
D – Minimum expected difference between the two means
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Power = 0.95 (95%)
= 72
Since we are doing a non–parametric analysis, power efficacy of 5% extra was also
considered. Since we expected a loss of follow up in approximately 10 % of patients, the
sample size was upsized by 10%. Hence the total sample size has been upsized to 82.
As the same group act as the control and comparator the sample size of one group is
41, ie, 41 patients were studied pretreatment and posttreatment.
4.7. INCLUSION CRITERIA:
a. Patients with symptoms suggestive of laryngopharyngeal reflux disease with a
reflux symptom index of 3 or more in any of the symptom scores.
b. Patients with symptoms suggestive of laryngopharyngeal reflux disease with a
reflux finding score of more than 7 as per laryngeal endoscopic examination.
c. Patients who were between the age group of 18 and 80.
4.8. EXCLUSION CRITERIA:
a. Those who were taking proton pump inhibitors for the past one month.
b. Patients who were hypersensitive to proton pump inhibitors.
c. Those who were on any regular drugs.
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d. Pregnant women.
e. Those who did not give consent.
f. Patients below 18 years of age.
g. Patients above 80 years of age.
h. Patients with other co-existing laryngeal pathology.
4.9. PARAMETERS TO BE STUDIED:
4.9.1. Reflux symptom index1: within the past month, how did the following
problems affect the patient? It was ranked from 0 to 5 (0- no problem to 5- severe
problem)
o Hoarseness or a problem with your voice
o Clearing of throat
o Excess mucous production in the throat or postnasal drip
o Difficulty in swallowing food, liquid, or pills
o Coughing after you have eaten or after lying down
o Breathing difficulty / choking episodes
o Troublesome/ annoying cough
o Sensation of something sticking in your throat or a lump in your throat
o Heartburn, chest pain, indigestion or stomach acid coming up
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4.9.2. Reflux finding score1: (endoscopic grading scale for laryngopharyngeal reflux
disease) score 0-26- more than 7 is significant
Subglottic edema 0 (Absent) 2 (Present)
Ventricular edema 0 (None) 2 (Partial) 4 (Complete)
Erythema/hyperemia 0 (None) 2 (Arytenoids only) 4 (Diffuse)
Vocal fold edema 0 (None) 1 (Mild) 2 (Moderate) 3 (Severe) 4 (Polypoid)
Diffuse laryngeal edema 0 (None) 1 (Mild) 2 (Moderate) 3 (Severe) 4 (Obstructing)
Posterior commisure
hypertrophy
0 (None) 1 (Mild) 2 (Moderate) 3 (Severe) 4 (Obstructing)
Granuloma/granulation
tissue 0 (Absent) 2 (Present)
Thick endolaryngeal
mucus 0 (Absent) 2 (Present)
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4.10. STATISTICAL ANALYSIS
Data was entered into Microsoft Office Excel 2007 for windows 7
SPSS Version 17.0 for Windows was used to analyze the data
Quantitative variables were described by mean, sd, Median, minimum and
maximum.
Qualitative variables were described by percentage distribution.
For Scores with non-normal (Non-Gaussian) distribution non-parametric test,
Wilcoxon’s signed rank test was used for comparison of pretreatment and
posttreatment scores.
Between groups comparisons of quantitative variables were analyzed by t test or
ANOVA.
Paired comparisons of qualitative variables were analyzed by McNemar test.
A p - value of 0.05 was considered as level of significance.
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5. OBSERVATION AND RESULTS
In this study entitled ‘Effect of Proton Pump Inhibitors on Laryngopharyngeal Reflux
disease, 85 patients in the age group of 19 to 74 years were included.. The mean age was
43.7 years.
Out of all patients, 7 were lost to follow up after 6 weeks, and therefore reflux symptom
index and reflux finding scores were analyzed using the remaining 78 patients. But in the
sample size calculation we expected 10% would be lost to follow up, that is 8. According
to the statistics only 41 patients were required for the study. But there were 78 patients
with proper follow up. This figure is more than the number expected for the adequate
strength of the study.
TABLE:1
Distribution of Patients According to Age
Age in years Frequency Percent
<30 19 22.4
31-40 23 27.1
41-50 18 21.2
51-60 15 17.6
>60 10 11.8
Total 85 100.0
There were 85 patients in the age group of 19 to 74 years of age in the study with
a maximum number in the age group of 31-40 and least number in those above 60
years of age.
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FIGURE: 11
Pie Chart Showing Distribution of Patients According to Sex
Majority of patients presented with symptoms suggestive of Laryngo pharyngeal
Reflux Disease are females, constituting 68.2% (58 patients) against 31.8%
(27patients) were males.
Male
31.8% (27)
Female
68.2% (58)
SEX
Male
Female
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TABLE:2
Distribution of Patients According to Educational Qualification
Education Frequency
Below high school 25
Higher secondary 33
Degree or above 27
Total 85
FIGURE: 12
Pie Chart Showing Distribution of Patients According to Educational
Qualification
As per the percentage of highest educational qualification possessed 29.4% (25 patients)
were below high school level, 38.8% (33 patients) were possessing higher secondary
education and 31.8% (27 patients) were having degree or above.
29.4% (25)
38.8% (33)
31.8% (27)
Education
Below high school
Higher secondary
Degree or above
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FIGURE: 13
Pie Chart Showing Distribution of Patients According to Habituation to
Smoke
In the study group 81.2% (69 patients) were non-smokers & 18.8% (16 patients)
were smokers.
Yes
18.8% (16)
No
81.2% (69)
SMOKING
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FIGURE: 14
Pie Chart Showing Distribution of Patients According Habituation to
Alcoholism
In the study group 69 (81.2%) people were non-alcoholics and 16 (18.8%) were
alcoholics.
Yes
18.8% (16)
No
81.2% (69)
Alcoholism
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FIGURE: 15
Pie Chart Showing Distribution of Patients According to Habituation to
Chew Tobsacco
It was observed that in study population most of the people were non-tobacco
chewers (90.6%). Only 8 people were tobacco chewers.
Yes
9.4% (8)
No
90.6% (77)
TOBACCO CHEWING
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FIGURE: 16
Distribution of Patients According to Status of Taking Fried Food
The above pie chart shows 51 (60%) people used to take fried food in contrast to
34 (40%) who won’t take.
Yes
60.0% (51)
No
40.0% (34)
FRIED FOOD CONSUMPTION
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FIGURE: 17
Distribution of Patients According to Status of Taking Fatty Food
In comparison of fatty food consumption in study population it was observed that 37.6%
(32 patients) were fatty food consumers. 62.4% (53 patients) were non-fatty food
consumers.
Yes
37.6% (32)
No
62.4% (53)
FATTY FOOD
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FIGURE: 18
Distribution of Patients According to Status of Coffee Consumption
In the study population 32 people (37.6%) used to drink coffee. 53 people (62.4%) won’t
drink.
Yes
37.6% (32)
No
62.4% (53)
COFFEE CONSUMPTION
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FIGURE: 19
Distribution of Patients According to Status of Spicy Food Consumption
In study population, majority of the people (47 patients ie, 55.3%) used to eat spicy food.
38 patients (44.7%) were non-spicy food consumers.
Yes
55.3% (47)
No
44.7% (38)
SPICY FOOD CONSUMPTION
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TABLE: 3
Comparison of Reflux Symptom Index among Pre treatment and Post
treatment Group
Reflux Symptom Index Pre treatment Post treatment
Mean 20.2 11.2
SD 4.6 4.5
Minimum 10.0 3.0
First quartile 17.0 9.0
Median 20.0 11.0
Third quartile 23.0
13.0
Maximum 31 23
Wilcoxon signed Rank test – z 7.483
p <0.001
Table 3 compares reflux symptom index of pre treatment and post treatment
groups. The mean pre treatment symptom index of 20.2 was reduced to 11.2. The
minimum score in the pre treatment group was 10 while that of the post treatment
group was 3. The maximum score in the pre treatment group was 31 while that of
post treatment group was 23. All the scores were analyzed using Wilcoxon signed
rank test which gave a p value <0.001 which is highly significant
Results
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FIGURE: 20
Boxplot Diagram Describing Reflux Symptom Index
Among Pretreatment and Post Treatment Group
Lower and upper end of the whisker represents minimum and maximum index. Lower
border of the box represents First quartile and the upper border represents the Third
quartile and the middle line (the line of separation of the two coloured box) represents
the median index.
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TABLE: 4
Comparison of Symptom Index for Hoarseness between Pre & Post
treatment Group
Index for
Hoarseness
Pre treatment Post treatment
N % N %
0 36 42.4 29 37.2
1 7 8.2 22 28.2
2 6 7.1 10 12.8
3 9 10.6 16 20.5
4 14 16.5 1 1.3
5 13 15.3 0 0
Lost follow up 7
Total 85 100.0 85 100
The symptom indices for hoarseness were graded according to severity from 0 to 5. In the
pretreatment study group, 36 people had a hoarseness index of 0, i.e., without any
complaints of hoarseness, followed by scores of 1-5 in a distribution of 7, 6, 9, 14 &13
which improved to 22, 10, 16, 1& 0 in the post treatment group. The 7 people lost to
follow up belonged to the group with no complaints .There was a significant reduction in
symptom index in pretreatment and post treatment groups. Wilcoxon signed rank test
showed , z value=4.923 and p<0.001.
Wilcoxon signed Rank Test
z=4.923 P<0.001
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TABLE: 5
Comparison of Symptom Index for Clearing Throat between Pre & Post
Treatment Group
Index for Clearing
Throat
Pre treatment Post treatment
N % N %
0 0 0 2 2.6
1 4 4.7 23 29.5
2 6 7.1 42 53.8
3 43 50.6 8 10.3
4 32 37.6 3 3.8
5 0 .0 0 .0
Lost follow up 7
Total 85 100.0 85 100
In the pretreatment study group maximum number of subjects, 43 people (50.6%) had a
score of 3. Pre treatment clearing throat symptom index scores 0, 1, 2, 3, 4, and 5 were 0,
4,16, 43, 32, & 0 respectively and post treatment scores for the same were 2, 23, 42, 8, 3,
0, &7 respectively. There was a significant reduction in clearing throat symptom index
pretreatment and post treatment with a p value of <0.001 when analyzed by wilcoxon
signed rank test.
Wilcoxon signed Rank Test
z=6.487 P<0.001
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TABLE: 6
Comparison of Symptom Index for Excess Mucous Production between Pre
& Post Treatment Group
Index for Excess
Mucous
Production
Pre treatment Post treatment
N % N %
0 6 7.1 12 15.4
1 17 20.0 31 39.7
2 14 16.5 26 33.3
3 26 30.6 9 11.5
4 19 22.4 0 0
5 3 3.5 0 0
Lost follow up 7
Total 85 100.0 85 100
In the study group , pretreatment index scores for excess mucous production that is 0, 1,
2, 3, 4, and 5 were, 6, 17,14, 26, 19, & 3 respectively, with maximum number of patients
having a score of 3.Those with post treatment index scores of 0, 1, 2, 3 were 12, 31,
26,&9 respectively. These values were analyzed using Wilcoxon signed Rank test & a
pvalue <0.001 was obtained,,which was statistically significant.
Wilcoxon signed Rank Test
z=6.487 P<0.001
Results
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TABLE: 7
Comparison of Symptom Index for Difficulty in Swallowing between Pre &
Post Treatment Group
Index for Difficulty
in swallowing
Pre treatment Post treatment
N % N %
0 39 45.9 55 70.5
1 23 27.1 14 17.9
2 11 12.9 6 7.7
3 5 5.9 2 2.6
4 5 5.9 1 1.3
5 2 2.4 0 .0
Lost follow up 7
Total 85 100.0 85 100
There were 12 patients in the pretreatment group with scores more than 3 which was
reduced to 3 post treatment. There were no patients with score of 5 in the post treatment
group,but pretreatment group had 2.The p value obtained was <0.001 which was
significant.
Wilcoxon signed Rank Test
z=4.665 P<0.001
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TABLE: 8
Comparison of Symptom Index for Cough after Eating between Pre & Post
Treatment Group
Index for Cough
After Eating
Pre treatment Post treatment
N % N %
0 28 32.9 38 48.7
1 20 23.5 21 26.9
2 17 20.0 16 20.5
3 11 12.9 3 3.8
4 9 10.6 0 0
5 0 0 0 .0
Lost follow up 7
Total 85 100.0 85 100
The above table showes 20 people with score of 3 or more in the pre treatment group
which was reduced to 3 in the post treatment group. All the values were analysed and it
gave a p value <0.001 which is highly significant ,with a significant reduction in the pre
treatment and post treatment group.
Wilcoxon signed Rank Test
z = 5.395 P<0.001
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TABLE: 9
Comparison of Symptom Index for Breathing Difficulty between Pre & Post
Treatment Group
Index for
Breathing
Difficulty
Pre treatment Post treatment
N % N %
0 52 61.2 58 74.4
1 17 20.0 16 20.5
2 7 8.2 4 5.1
3 7 8.2 0 0
4 2 2.4 0 0
5 0 .0 0 0
Lost follow up 7
Total 85 100.0 85 100
When comparing the Reflux symptom index for breathing difficulty we observed that
there were no patients with a score of 5 in both pre treatment as well as post treatment
group. There were 9 patients in the pre treatment group with a score of 3 and 4 combined,
while in the post treatment group there were no patients with a score of 3 and 4.
Wilcoxon signed rank test gave a p value of <0.001 which is highly significant
Wilcoxon signed Rank Test
z=3.732 P<0.001
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TABLE: 10
Comparison of Symptom Index for Annoying Cough between Pre & Post
Treatment Group
Index for Annoying
Cough
Pre treatment Post treatment
N % N %
0 6 7.1 19 24.4
1 18 21.2 24 30.8
2 18 21.2 27 34.6
3 26 30.6 6 7.7
4 15 17.6 2 2.6
5 2 2.4 0 0
Lost follow up 7
Total 85 100.0 85 100
The study revealed 43 patients having a pre treatment score of 3 or more for the index
for annoying cough which was found to be reduced to 8 in the post treatment group with
no patients having a score of 5. It showed a significant reduction in the index for
annoying cough following treatment. Wilcoxon signed rank test showed a z value of
6.128 whose corresponding p value was <0.001 which was statistically significant.
Wilcoxon signed Rank Test
z=6.128 P<0.001
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TABLE: 11
Comparison of Symptom Index for Foreign body Sensation Throat between
Pre & Post Treatment Group
Index for Foreign
body Sensation
Throat
Pre treatment Post treatment
N % N %
0 2 2.4 3 3.8
1 0 0 14 17.9
2 10 11.8 40 51.3
3 15 17.6 13 16.7
4 29 34.1 7 9.0
5 29 34.1 1 1.3
Lost follow up 7
Total 85 100.0 85 100
85.9% of the study group (73 patients) had a reflux symptom index for foreign body
sensation throat of, 3 or more, which was reduced to 26.9% (21 patients) in the post
treatment group. There was a significant reduction in the post treatment symptom index
for foreign body sensation throat following treatment. Wilcoxon signed rank test showed
a p value of <0.001 which was highly significant.
Wilcoxon signed Rank Test
z=6.923 P<0.001
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TABLE: 12
Comparison of Symptom Index for Heart Burn between Pre & Post
Treatment Group
Index for Heart
Burn
Pre treatment Post treatment
N % N %
0 8 9.4 6 7.7
1 8 9.4 26 33.3
2 11 12.9 31 39.7
3 14 16.5 11 14.1
4 29 34.1 3 3.8
5 15 17.6 1 1.3
Lost follow up 7
Total 85 100.0 85 100
The number of patients with lower score for heart burn that is a score <3 were 27 in the
pre treatment group which increased to 63 in post treatment group. On statistically
analysing the scores by wilcoxon signed rank test it gave high significance ,with p
value <0.001.
Wilcoxon signed Rank Test
z=6.557 P<0.001
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TABLE: 13
Comparison of Reflux Finding Score among Pre treatment and Post
treatment Group
Reflux Finding Score Pre treatment(N=85)
Post treatment
(N=78)
Mean 9.9 6.0
SD 3.7 4.1
Minimum 4.0 1.0
First quartile 7.0 3.8
Median 9.0 5.0
Third quartile 12.0 8.0
Maximum 20 20
Wilcoxon signed Rank test - z 7.133
p <0.001
Table 13 shows a comparison of Reflux Finding Scores in the pre treatment and Post
treatment groups. The mean score in the pre treatment group was 9.9. A reduction in the
mean pretreatment score to 6.0 is seen in the post treatment group. The standard deviation
among pre treatment and post treatment group were 3.7 and 4.1 respectively. The
Minimum score in pre treatment group was 4 where as in post treatment group it was 1.
The maximum value being, 20 for both the groups. All the values were analyzed
statistically, Wilcoxon signed test gave a p value <0.001 which was highly significant.
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FIGURE: 21
Boxplot Diagram Describing Reflux Finding Score
Among Pretreatment and Post Treatment Group
Lower and upper end of the whisker represents minimum and maximum index. Lower
border of the box represents First quartile and the upper border represents the Third
quartile and the middle line ( the line of separation of the two coloured box) represents
the median index.
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TABLE: 14
Comparison of Subglottic Edema finding Score between Pre & Post Treatment
Group
SG EDEMA
SCORE
Pre treatment Post treatment
N % N %
Absent 49 57.6 64 82.1
Present 36 42.4 14 17.9
Lost to follow up 7
Total 85 100.0 85 100
In the endoscopic examination absent reflux finding score for subglotic edema
in the pretreatment group was 57.6% (49 patients), it increased to 82.1% (64
patients) in the post treatment group. McNemar test was done and it was
significant with a p value <0.001.
McNemar test p<0.001
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TABLE: 15
Comparison of Ventricular Edema Finding Score between Pre & Post Treatment
Group
VENTRICULAR
EDEMA SCORE
Pre treatment Post treatment
N % N %
Absent 6 7.1 40 51.3
Partial 71 83.5 34 43.6
Complete 8 9.4 4 5.1
Lost to follow up 7
Total 85 100.0 85 100
The pretreatment reflux finding score with absent ventricular edema was seen in 6
patients (7.1%), 71 patients (83.5%) had partial ventricular edema and 8 patients (9.4%)
had complete ventricular edema. In the post treatment group those with absent
ventricular edema increased from 6 to 40 (7.1% to 51.3%) and the number of patients
with partial and complete ventricular edema became 34 (43.6%) and 4 (5.1%)
respectively. The p value obtained by analyzing the pre treatment and post treatment
scores of ventricular edema was <0.001 by McNemar test, which is highly significant.
McNemar test p<0.001
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TABLE: 16
Comparison of Erythema Finding Score between Pre & Post Treatment Group
ERYTHEMA
SCORE
Pre treatment Post treatment
N % N %
Absent 2 2.4 13 16.7
Arytenoids only 42 49.4 55 70.5
Diffuse 41 48.2 10 12.8
Lost to follow up 7
Total 85 100.0 85 100
In the present study there were 42 patients with erythema in arytenoids, 41 patients had
diffuse erythema and only 2 patients were without any erythema in the pretreatment
group. But in the post treatment group there was a drastic reduction in the number of
patients with diffuse erythemia , i.e upto 10 (12.8%) .The number of patients without
any erythema increased to 13 (16.7%) while that in the pretreatment group were only 2
(2.4%).
McNemar test p<0.001
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TABLE: 17
Comparison of Vocal Fold Edema Finding Score between Pre & Post Treatment
Group
VF EDEMA
SCORE
Pre treatment Post treatment
N % N %
Absent 2 2.4 25 32.1
Mild 65 76.5 42 53.8
Moderate 14 16.5 11 14.1
Severe 4 4.7 0 0
Lost to follow up 7
Total 85 100.0 85 100
In our study in pretreatment group there were 65 patients (76.5%) with mild vocal fold
edema, and 2 (2.4%), 14 (16.5%), 4 (4.7%) with absent moderate and severe reflux
finding score respectively. In the post treatment group there were no patients with severe
vocal fold edema and 11 (14.1%) and 42 (53.8%) had moderate and mild vocal fold
edema. There were 25 (32.1%) patients with no vocal fold edema in the post treatment
group. McNemar test gave a p value <0.001 which is highly significant for the
percentage reduction in pre and post treatment scores.
McNemar test p<0.001
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TABLE: 18
Comparison of Diffuse Laryngeal Edema Finding Score between Pre & Post
Treatment Group
DLE SCORE Pre treatment Post treatment
N % N %
Absent 22 25.9 51 65.4
Mild 57 67.1 22 28.2
Moderate 1 1.2 4 5.1
Severe 5 5.9 1 1.3
Lost to follow up 7
Total 85 100.0 85 100
In the pretreatment group there were 57 patients (67.1%) with mild diffuse laryngeal
edema and 22 patients (25.9%) without any laryngeal edema. There were 5 patients
(5.9%) with severe and 1 patient (1.2%) with moderate laryngeal edema in pretreatment
group. In the post treatment group 51 (65.4%) patients had absent diffuse laryngeal
edema. There was a significant reduction in the reflux finding score among pre treatment
and post treatment group, and the McNemar test showed a p value of <0.001.
McNemar test p<0.001
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TABLE: 19
Comparison of Posterior Commisure Hypertrophy Finding Score between Pre &
Post Treatment Group
Posterior
commisure
hypertrophy
Pre treatment Post treatment
N % N %
Absent 4 4.7 7 9.0
Mild 36 42.4 55 70.5
Moderate 33 38.8 11 14.1
Severe 12 14.1 5 6.4
Lost follow up 7
Total 85 100.0 85 100
a) In this study 36 patients (42.2%) and 33 patients (38.8%) had mild and
moderate posterior commisure hypertrophy. In the posttreatment group there
was an improvement in reflux finding score. There was a reduction in number
of patients with severe posterior commisure hypertrophy between pre treatment
(12 patients) and post treatment groups (5 patients). McNemar test gave a p
value <0.001.
McNemar test p<0.001
Results
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TABLE: 20
Comparison of Granuloma Finding Score between Pre & Post Treatment Group
GRANULOMA Pre treatment Post treatment
N % N %
Absent 81 95.3 76 97.4
Present 4 4.7 2 2.6
Lost follow up 7
Total 85 100.0 85 100
There were only 4 patients (4.7%) with granuloma in pre treatment group,
whereas in the post treatment group it reduced to 2, ie a reduction of 50%. But
McNemar test gave a p value=0.500 which is not significant.
McNemar test p=0.500
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TABLE: 21
Comparison of Thick Endolaryngeal Mucosa Finding Score between Pre & Post
Treatment Group
Thick Endolaryngeal
mucosa
Pre treatment Post treatment
N % N %
Absent 73 85.9 71 91.0
Present 12 14.1 7 9.0
Lost follow up 7
Total 85 100.0 85 100
There were 12 patients with thick endolaryngeal mucosa in the pretreatment group
which was reduced to 7 in the post treatment group. The reduction in the score was not
significant according to McNemar test (p=0.219)
McNemar test p=0.219
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TABLE: 22
Comparison of Percentage Reduction of Reflux Symptom Index Scores among
Males and Females
SEX N
Percentage reduction in
RSI
T P
Mean SD
Male 27 44.8 13.7
.218 0.828
Female 51 43.9 19.7
FIGURE: 22
Comparison of Percentage Reduction of Reflux Symptom Index Scores among
Males and Females
The above table and figure shows a mean percentage reduction of 44.8% in males
and 43.9 among females. Statistically there is no significant relation between the
reduction in reflux finding index and sex. ANOVA gave a p value of 0.823
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TABLE: 23
Comparison of Percentage Reduction in Reflux Finding Score among Males and
Females
FIGURE: 23
Comparison of Percentage Reduction in Reflux Finding Score among Males and
Females
The above Table and Figure a mean percentage reduction of 43.4 among males
and 39.1 among females. On statistically analyzing the mean reduction in reflux
finding score it gave a p value of 0.487 which is not significant.
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SEX N
Percentage reduction in
RFS T P
Mean SD
Male 27 43.4 24.2
.699 0.487
Female 51 39.1 26.7
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TABLE: 24
Percentage of Reduction in Reflux Symptom Index Based on Habits
Table 24 shows Mean percentage reduction in reflux Symptom Index among different
habituations. This study did not show any relation with habits and reduction in Reflux
symptom score after treatment. The p values for smoking, alcoholism and tobacco
chewing after analysis were >0.05 which is not statistically significant
N
Percentage reduction in
SI
t p
Mean SD
Smoking
Yes 16 42.1 18.2
.534 0.595
No 62 44.8 17.8
Alcoholism
Yes 16 44.6 17.9
.092 0.927
No 62 44.1 17.9
Tobacco
Chewing
Yes 6 41.2 18.2
.431 0.668
No 72 44.5 17.8
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Figure: 24
Bar Diagram showing percentage reduction in Reflux Symptom Index among
Smokers, Alcoholics and Tobacco Chewers
The above bar diagram shows a mean percentage reduction of 42.1 among
smokes, 44.6% reduction in mean score among alcoholics and 41.2% reduction
among those who chew tobacco.
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Table 25
Percentage of Reduction in Reflux Symptom Index According to Food Habits
Table 25 shows the percentage of reduction in reflux symptom index according to food
habits. In those who consume fatty foods there is a significant reduction in p value,
whereas for other food habits the reduction in score is not statistically significant. No
strict instructions regarding modification of dietary habits were given to the sample
population. So the comparison of reduction in score pre and post treatment according to
food habits is outside the scope of this study.
N
Percentage reduction in
SI
t P
Mean SD
Fried food
Yes 46 45.7 17.3
.892 0.375
No 32 42.1 18.4
Fatty food
Yes 27 50.0 16.3
2.139 0.036
No 51 41.1 17.9
Coffee
Yes 30 46.3 17.7
.831 0.409
No 48 42.9 17.9
Spicy
food
Yes 44 44.4 16.6
.093 0.926
No 34 44.0 19.4
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Figure: 25
Bar Diagram showing percentage reduction in Reflux Symptom Index According to
Food Habits
Figure 25 shows the percentage reduction of reflux symptom index according to
food habits. There was a 50% reduction among fatty food consumers, 46.3%
reduction among those who consume coffee. 45.7% and 44.4% respectively for
fried food consumers and spicy food consumers.
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TABLE:26
Percentage of Reduction in Reflux Finding Score Among Groups Based on
Habituations
Table 26 shows the comparison of reduction in reflux finding score among groups based
on habituations. It does not show any statistically significancant reduction in reflux
finding Scores among the group with habituations. As no strict instructions were given
regarding modification of habituations, the comparison of the same is beyond the scope
of this study.
N
Percentage reduction in
RFS
t P
Mean SD
Smoking
Yes 16 36.7 23.4
.683 0.497
No 62 41.6 26.5
Alcoholism
Yes 16 39.1 22.5
.261 0.795
No 62 41.0 26.7
Tobacco
Chewing
Yes 6 32.1 21.9
.842 0.402
No 72 41.3 26.1
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Figure :26
Bar Chart Showing the Reduction in Reflux Finding Score Among Smokers,
Alcoholis and Tobacco Chewers
The above bar diagram shows a reduction of 36.7%, 39.1% and 32.1% reduction
in reflux finding score among groups based on habituations.
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TABLE: 27
Percentage of Reduction in Reflux Finding Score According to Food Habits
Table 27 shows the percentage in reflux finding score according to food habits. Even
though there is a reduction in the scores, it is not statistically significant. As no strict
instructions regarding , modification of food habits were given to the patient group; the
comparison of the reduction in reflux finding score according to food habits is outside the
scope of this study.
N
Percentage reduction in
RFS
T P
Mean SD
Fried Food
Yes 46 41.6 27.2
.419 0.677
No 32 39.1 24.0
Fatty Food
Yes 27 42.4 27.1
.432 0.667
No 51 39.7 25.3
Coffee
Yes 30 42.2 28.7
.426 0.671
No 48 39.6 24.1
Spicy Food
Yes 44 40.4 23.5
.077 0.939
No 34 40.9 28.8
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Figure 27
Percentage of Reduction in Reflux Finding Score according to food habits
On studying the percentage reduction in reflux finding score according to food habits,
there was 41.6%, 42.4%, 42.2% and 40.4% among those who take fried food, fatty food,
coffee and spicy food respectively.
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DISCUSSION:
The present study was aimed to evaluate the effect of Proton pump inhibitors on the
reflux symptom index and reflux finding score among those who suffer from
Laryngopharyngeal reflux disease.
This study included 2 groups each group comprising of 85 patients, of which the
pretreatment group acts as the control and the same patients after treatment act as the test
group. Those patients with other co-existing laryngeal pathology, patients who are hyper
sensitive to proton pump inhibitors, who are on proton pump inhibitor therapy for the past
one month and pregnant women were excluded from the study.
Table 28: Comparison of Mean age and Age group with maximum patients with other
studies
Our Study
Patigaroo SA et al.
(2011)
Mattoo O et al.
(2012)
Mean age 43.7 38.0 42.3
Age group with
maximum patients
31 – 40 31 – 40 31 – 40
In a study of 50 Indian patients with LPRD by Suhail Amin Patigaroo and colleagues
(Aligarh, Uttar Pradesh) in 2011; 40% belonged to the age group of 31-40 years with a
mean age being 38.[25] Another study by Mattoo O and colleagues (2012) in Srinagar
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showed a mean age of 42.3 years.[12] We also observed a peak incidence of LPRD in the 31-
40 years age group, with the mean age being 43.07 years. We had 22.4% in the age group of
less than 30 years, 21.2% in the age group of 41-50 years, 17.6% in the age group of 51-60
years and the least being (11.8%) in the age group of greater than 60 years.
Table 29: Comparison of Gender wise distribution with other studies
Our Study Belafsky et al. (2002) Patigaroo et al.
(2012)
Preetam
Chapitty
(2014)
Male Female Male Female Male Female Male female
31.8% 58.2% 56% 44% 40% 60% 49.8% 50.2%
Gender based distribution of the subjects in our study revealed that 31.8% were males
and 58.2% females. However Belafsky and colleagues in North Carolina, United States
(2002) showed a male predominance of 56% in his study of 25 patients.[15] In the Indian
context, Suhail A Patigaroo and colleagues (2012), observed that 60% of the patients with
LPRD were females.[25] Another study by Preetam Chappity and colleagues (2014)
conducted in New Delhi showed an almost equal distribution among males and females in
their study of 234 Indian patients with LPRD.[38]
An assessment of the educational qualification of the subjects showed that 29.4% that is
25 patients had only primary school education, 38.8% (33 patients) possessed higher
secondary education and 31.8% (27 patients) had a collegiate education.
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Among the 85 patients personal history of smoking was present in 18.8% (16 patients),
alcoholism 18.8% (16 patients) and tobacco chewing 9.4% (8 patients).
The association of LPRD with dietary habits was observed as follows. 60% i.e. 51
patients used to take fried food, 55% (47 patients) used to take spicy food, 37.6% (32
patients) used to take fatty food regularly and 37.6% (32 patients) used to drink coffee.
6.1. EFFECT OF TREATMENT ON THE OUTCOME
The effect of treatment of LPRD were assessed primarily based on Reflux Symptom
Index and Reflux finding Score
6.1.1. Effect of treatment on Reflux Symptom Index
In our study the mean reflux symptom index for pretreatment group was 20.2 and it
was reduced to 11.2 in the posttreatment group. Wilcoxons signed rank test was done
for the pretreatment and posttreatment group and it gave a z value of 7.483 and p <
0.001 which is highly significant.
Table 30: Comparison of change in Reflux Symptom Index with Other Studies
Our Study Belafsky et al. (2002) Mattoo et al. (2012)
Pretreatment Posttreatment Pretreatment Posttreatment Pretreatment Posttreatment
20.2 11.2 21.2 12.8 20.7 8.9
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A study by Belafsky and colleagues in North Carolina, United States among Americans
showed a reduction of mean Reflux symptom index from 21.2 to 12.8 among pretreatment
and posttreatment group.[15] Another study by Mattoo and colleagues in Indian population,
showed a reduction of mean RSI from 20.7 to 8.9 between pretreatment and posttreatment
group when treated with twice daily dose of PPI and Domperidone for a duration of 4
months.[12] The results obtained from both the studies were comparable to ours.
In our study an attempt has been made to compare the reduction in each component of the
reflux symptom index. There was no literature available where such a comparative pre and
posttreatment analysis of each component of the reflux symptom index has been done.
6.1.1.1.PRE & POSTTREATMENT COMPARATIVE ANALYSIS OF
COMPONENTS OF REFLUX SYMPTOM INDEX
a) Effect of treatment on the symptom index for hoarseness was assessed. In the
pretreatment group there were 13 patients with a score of 5 whereas in the
posttreatment group there was no one with the same. 14 patients in the pretreatment
group had a score of 4, whereas it was reduced to 1 in the posttreatment group.
Wilcoxon singed rank test was done and it showed a p value <0.001 which is highly
significant.
In a retrospective review of 105 known cases of LPRD of 3 years duration with
voice-related disorders by Thomas and Zubiaur (2013) in Texas on post treatment
patients concluded, a significant improvement in hoarseness among 5 %, mild
improvement 13%, no improvement 79% and worsening symptoms 3%. In his
study in addition to the reflux symptom index and reflux finding score he used
voice handicap index also.[63]
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b) On comparing the symptom for clearing throat there were no patients in both pre &
posttreatment group with score 5. There were 43 and 32 patients in the pretreatment
group with a score of 3 and 4 respectively, which was reduced to 8 and 3 in the
posttreatment group. These scores were also assessed using Wilcoxon signed rank
test and it was significant with a p value <0.001.
c) In our study the reflux symptom index in the pretreatment group for excess mucous
production was 19 and 3 for scores 4 and 5 respectively which was reduced to zero
in the posttreatment group for both the scores. Statistical analysis of the pre and
posttreatment scores showed significant reduction in the scores posttreatment with 6
weeks of proton pump inhibitors with a p value of <0.001.
d) On analyzing the reflux symptom index in the pretreatment group for difficulty in
swallowing the maximum number of patients were having a score <3. The
percentage of patients in the pretreatment group with scores 3 to 5 was 14.1% (12
patients) which was reduced to 3.8% (3 patients) in the posttreatment group. There
is a significant reduction in the index among the posttreatment group with a p value
<0.001 in Wilcoxon signed rank test.
e) Among the distribution of pretreatment symptom index for cough there were 23.5%
(20 patients) with a score of 3 or more, which was reduced to 3.8% (3 patients) in
the posttreatment group. Wilcoxon signed rank test was done for all the scores and
it showed significant reduction in the pretreatment and posttreatment symptom
index for cough after eating with a z value of 5.395 and p < 0.001
f) In our study the comparison of pretreatment symptom index for breathing difficulty,
there were 8.2% (9 patients) in the pretreatment group with a score of 3 or more.
There was a complete reduction in scores from 3 to 5 in the posttreatment group.
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There were no patients with score 5 in both the groups. Wilcoxon signed rank test
was done for all the scores and it showed significant reduction in the pretreatment
and posttreatment symptom index for cough after eating with a z = 3.732 and
p<0.001
g) The analysis of symptom index for annoying cough in the pretreatment group
showed a maximum number of patients (26) constituting 30.6% of the pretreatment
group with score 3. There were 43 patients in the pretreatment group with a score of
3 or more which was reduced to 8 in the posttreatment group. Wilcoxon signed
ranked test showed z = 6.128 and a p value <0.001 which is highly significant
h) 73 patients in the pretreatment group with a symptom index of 3 or more for foreign
body sensation throat which was reduced to 21 in posttreatment group. Wilcoxon
signed Rank test gave a z value of 6.923 and p value <0.001 which is significantly
high.
i) On comparing the symptom index for heart burn, there were 58 patients in the
pretreatment group with score varying from 3-5, it was reduced to 15 in the
posttreatment group. Here also Wilcoxon signed Rank test was significant with a z
value of 6.557 and p value <0.001
6.1.2. Effect of treatment on Reflux finding score
In our study the comparison of reflux symptom index of pretreatment group with that
of the posttreatment group showed a difference of 3.9 i.e. a reduction from 9.9 to 6
with 6 weeks of treatment. The data was analysed used Wilcoxons signed rank test and
it showed a p value <0.001 which is highly significant.
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Table 31: Comparison of pretreatment and posttreatment reflux finding score
with other study
Our Study Patigaroo et al.
Pretreatment Posttreatment Pretreatment Posttreatment
9.9 6.0 12 6.5
Suhail A Patigaroo and colleagues’ in their study of 50 Indian patients with LPRD,
showed a mean reduction in Reflux finding score from 12 in the pretreatment to 6.5 in
the posttreatment group. These values are comparable to our study.[25]
We also made an attempt to compare each component of the Reflux finding score
among the pretreatment and posttreatment group, which was not done in previous
studies.
6.1.2.1.PRE & POSTTREATMENT COMPARATIVE ANALYSIS OF
COMPONENTS OF REFLUX FINDING SCORE
a) On endoscopic examination, pretreatment group had 42.4% (36 patients) with
subglottic edema as compared to 17.9% (14 patients) in the posttreatment group.
McNemar test was done and it was significant with a p value <0.001.
b) Our study also gave a 50% reduction in the number of patients with complete
ventricular edema on endoscopic evaluation after treatment. There was a
significant improvement on treatment with an increase in the number of patients
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with absent ventricular edema from 6 to 40 (7.1% to 51.3%). The p value obtained
by analyzing the pretreatment and posttreatment scores of ventricular edema was
<0.001 by McNemar test, which is highly significant.
c) In our study there were 42 patients with erythema in the arytenoids, 41 patients
with diffuse erythema and 2 patients without any erythema in the pretreatment
group. In the posttreatment group there was a drastic reduction in the number of
patients with diffuse erythema from 41 to 10 (ie 48.2% to 12.8%). McNemar test
gave a p value <0.001.
d) There were 21.1% (18 patients) with moderate to severe vocal fold edema in the
pretreatment group. It was reduced to 14.1% (11 patients) in the posttreatment
group. There were no patients with severe vocal fold edema in the posttreatment
group. McNemar test showed a p value <0.001
e) Our study showed a reduction in the endoscopic score for diffuse laryngeal edema.
In the pretreatment group there were 5 patients with severe diffuse laryngeal
edema, which was reduced to 1 in the posttreatment group. McNemar test showed
a p value <0.001 which is highly significant.
f) When comparing the reflux finding index for posterior commissure hypertrophy,
45 patients in the pretreatment group had moderate to severe posterior commissure
hypertrophy, which was reduced to 16 patients posttreatment. There was a
reduction in the number of patients with severe posterior commissure hypertrophy
from 12 patients in the pretreatment to 5 patients in the posttreatment group.
McNemar test gave a p value <0.001.
g) In our study there were only 4 patients (4.7%) with granuloma in the pretreatment
group. Though in the posttreatment group it was considerably reduced by 50%
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(from 4 to 2 patients only) a statistical significance could not be derived (p = 0.50)
which could probably be attributed to the fewer number of patients with
granuloma.
h) There were 12 patients with thick endolaryngeal mucosa in the pretreatment group
in our study. Though this was reduced to 7 with treatment, it was not significant
according to McNemar test (p=0.219)
7. Our study didn’t show any gender difference, in the reduction of reflux symptom index or
reflux finding score.
8. There was no relation with dietary habits and habituation in the reduction of reflux
symptom index or reflux finding score, except for an incidental finding of a statistically
significant p value of 0.036 in patients who consume fatty food. No strict dietary and
lifestyle modification/ restrictions were imposed on the patients. So the comparison
with dietary habits and habituations is outside the scope of this study.
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6.2. STRENGTH OF THE STUDY
This is a prospective study
We use reliable, accepted, commonly used diagnostic tool.
The outcomes were assessed using objective criteria.
The pre and posttreatment findings were verified by a senior who was not below the
post of Assistant Professor – who was not the part of the study.
6.3. LIMITATION OF THE STUDY
This is not a randomized control trial, because there is no other active equivalent
treatment for laryngopharyngeal reflux.
No strict habitual restrictions were imposed on the study population.
No strict dietary modifications were imposed on the subjects.

Conclusion
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7. CONCLUSIONS
The conclusions drawn from the study carried out and results obtained are as follows:
LPRD is more common in the age group of 31-40 years.
LPRD is more common among females.
Among the symptoms clearing of throat was the most common.
Proton pump inhibitors are highly effective in controlling laryngeal reflux symptom index
and laryngeal reflux finding score.

Summary
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SUMMARY
This hospital based prospective study with quasi experimental design to evaluate
the effect of proton pump inhibitors on laryngopharyngeal reflux disease included 85
patients between the age group of 19 and 74. In our study we found out that,
laryngopharyngeal reflux symptom score is reliable in identifying patients with LPRD.
Reflux finding score is a very useful diagnostic tool to diagnose and evaluate the effect of
proton pump inhibitors.
In our study we found that clearing of throat was the most common presenting
symptom. Foreign body sensation in throat was also found to be common. Heart burn,
excessive mucous production and annoying cough were also frequently experienced.
Breathing difficulty and difficulty in swallowing were experienced by very few people.
The role of fried food was found to be significant in Laryngopharyngeal Reflux
Disease.
Analysis of the results in the study showed a significant improvement in reflux
symptom index and reflux finding score with the use of proton pump inhibitors. There
was a significant improvement in each component of the reflux symptom index and
reflux finding score with treatment.
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Abbreviations
LPRD - Laryngopharyngeal Reflux Disease
GERD - Gastroesophageal Reflux Disease
PPI - Proton pump inhibitor
LPR - Laryngo Pharyngeal Reflux
EER - Extra Esophageal Reflux
UES - Upper Esophageal Sphincter
LES - Lower Esophageal Sphincter
TLESR - Transient Lower Esophageal Sphincter Relaxation
GER - Gastro Esophageal Reflux
RSI - Reflux Symptom Index
RFS - Reflux Finding Score
TNE - Trans Nasal Endoscopy
ELISA - Enzyme Linked Immuno Sorbent Assay
LFD - Lateral Flow Device
MII - Multichannel Intraluminal Impedence
RAI - Reflux Area Index
EE - Endoscopic-positive Esophagitis
FSSG - Frequency Scale for the Symptoms of Gastroesophageal Reflux Disease
TFL - Transnasal Flexible Laryngoscopy
EGD - Esophagogastroduodenoscopy
SD - Standard Deviation
SPSS - Statistical Package for Social Sciences
XIX | P a g e
PROFORMA
Name: Age: Gender:
OP number: Study number:
Educational Status:
1. Presenting Complaints – Grade from 0 to 5 (0- no problem 5- severe problem)
Symptoms Pre Treatment Post Treatment
Hoarseness of voice
Clearing throat
Excess throat mucus/post nasal drip
Difficulty in swallowing food, pills, liquid
Cough after eating/ lying down
Annoying cough
Breathing difficulty/ choking episodes
Sensation of something sticking in throat
Heart burn/ chest pain/ stomach acid coming up
Date
Laryngeal symptom index (Pre treatment) :
Laryngeal symptom index (Post treatment) :
2. Personal history/ dietry history
Using tobacco :
Using alcohol :
Eating fried foods :
Eating fatty foods :
Drinking coffee :
Eating spicy food :
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3. Endoscopy
Reflux finding score Pre
Treatment
Post
treatment
Reference
Subglottic edema 0- Absent; 2 present
Erythema/hyperemia 1- Arytenoids only; 4- diffuse
Ventricular edema 2- Partial; 4- complete
Vocal fold edema 1-Mild; 2- Moderate; 3- Severe; 4- Obstructing
Diffuse laryngeal edema 1-Mild; 2- Moderate; 3- Severe; 4- Obstructing
Post. commissure hypertrophy 1-Mild; 2- Moderate; 3- Severe; 4- Obstructing
Granuloma/granulation tissue 0- Absent; 2 Present
Thick endolaryngeal mucus 0- Absent; 2 Present
Reflux finding score (Pre treatment) :
Reflux finding score (Post treatment) :
Other finding
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CONSENT FORM
The principal investigator has explained to me in writing the details of the study“Effect
of proton pump inhibitors on Laryngopharyngeal reflux disease – A prospective study” to be
conducted in the department of ENT, Sree Mookambika Institute of Medical Sciences,
Kulasekharam. He has explained to me that by being a part of this study no new medication will
be tried out on me. I am aware of my right to opt out of this study at any stage without any
hindrance to my ongoing treatment. No additional financial burden will be placed on me by
being part of this study. Data collected for the study will be kept under strict confidentiality and
would reflect on general statistical evaluation only and would not reveal any personal details.
The principal investigator has also explained in detail about the procedure, flexible
nasopharyngo laryngoscopy and the possible adverse effects associated with it. Keeping the
above facts in mind I, whole heartedly, without any compulsion agree to participate in this
study.
Signature of the patient
Signature of the investigator
Signature of the witness
Address of the patient
SlNo.
MRNo.
Age
Sex
EducationalQualification
Smoking
Alcohol
TobaccoChewing
FriedFood
FattyFood
Coffee
SpicyFood
HoarsenessofVoice
ClearingThroat
ExcessMucousProduction
DifficultyinSwallowing
Coughaftereating
BreathingDifficulty
AnnoyingCough
ForeignbodysensationThroat
HeartBurn
SymptomIndexPretreatment
Subglotticedema
Ventricularedema
Erythema
Vocalfoldedema
Diffuselaryngealedema
Posteriorcommisurehypertrophy
Granuloma
Thickendolaryngealmucosa
RFSpretreatment
HoarsenessofVoice-post
ClearingThroat-post
ExcessMucousProduction-post
DifficultyinSwallowing-post
Coughaftereating-post
BreathingDifficulty-post
AnnoyingCough-post
ForeignbodysensationThroat-post
HeartBurn-post
SymptomIndexPosttreatment
Subglotticedema-post
Ventricularedema-post
Erythema-post
Vocalfoldedema-post
Diffuselaryngealedema-post
Posteriorcommisurehypertrophy-post
Granuloma-post
Thickendolaryngealmucosa-post
RFSposttreatment
SymptomIndexDifference
RefluxFindingScoreDifference

Key to Master Chart
MR No Medical Record Number
Smoking Patients who used to smoke
Alcohol Patients who used to consume alcohol
Tobacco chewing Patients who used to chew tobacco
Fried food Patients who used to take fried food
Fatty food Patients who used to take fatty food
Coffee Patients who used to consume coffee
Spicy food Patients who used to take spicy food
Hoarseness of voice Pretreatment symptom index for hoarseness of voice
Clearing throat Pretreatment symptom index for clearing of throat
Excess mucous
production
Pretreatment symptom index for excess mucous
production
Difficulty in
swallowing
Pretreatment symptom index for difficulty in
swallowing
Cough after eating Pretreatment symptom index for cough after eating
Breathing Difficulty Pretreatment symptom index for breathing difficulty
Anoying cough Pretreatment symptom index for annoying cough
Foreign body
sensation throat
Pretreatment symptom index for foreign body
sensation of throat
Heart Burn Pretreatment symptom index for Heart burn
Symptom index
pretreatment
Pretreatment symptom index
Subglottic edema Pretreatment reflux finding score for subglottic
edema
Ventricular edema Pretreatment reflux finding score for ventricular
edema
Erythema Pretreatment reflux finding score for erythema
Vocal fold edema Pretreatment reflux finding score for vocal fold
edema
Diffuse laryngeal
edema
Pretreatment reflux finding score for Diffuse
laryngeal edema
Posterior commisure
hypertrophy
Pretreatment reflux finding score for posterior
commisure hypertrophy
Granuloma Pretreatment reflux finding score for Granuloma
Thick endolaryngeal
mucosa
Pretreatment reflux finding score for thick
endolarygeal mucosa
RFS pretreatment Pretreatment Reflux Finding Score
Hoarseness of voice-
post
Posttreatment symptom index for hoarseness of voice
Clearing throat-post Posttreatment symptom index for clearing of throat
Excess mucous
production-post
Posttreatment symptom index for excess mucous
production
Difficulty in
swallowing-post
Posttreatment symptom index for difficulty in
swallowing
Cough after eating- Posttreatment symptom index for cough after eating
post
Breathing Difficulty-
post
Posttreatment symptom index for breathing difficulty
Anoying cough-post Posttreatment symptom index for annoying cough
Foreign body
sensation throat-post
Posttreatment symptom index for foreign body
sensation of throat
Heart Burn-post Posttreatment symptom index for Heart burn
Symptom index
posttreatment
Posttreatment reflux symptom index
Subglottic edema-post Posttreatment reflux finding score for subglottic
edema
Ventricular edema-
post
Posttreatment reflux finding score for ventricular
edema
Erythema-post Posttreatment reflux finding score for erythema
Vocal fold edema-
post
Posttreatment reflux finding score for vocal fold
edema
Diffuse laryngeal
edema-post
Posttreatment reflux finding score for Diffuse
laryngeal edema
Posterior commisure
hypertrophy-post
Posttreatment reflux finding score for posterior
commisure hypertrophy
Granuloma-post Posttreatment reflux finding score for Granuloma
Thick endolaryngeal
mucosa-post
Posttreatment reflux finding score for thick
endolarygeal mucosa
RFS posttreatment Posttreatment Reflux Finding Score
Symptom index
difference
Difference between reflux symptom index pre and
post treatment
Reflux finding score
difference
Difference between reflux finding score pre and post
treatment
